

**Sponsor**

Novartis Pharmaceuticals

Generic Drug Name

Inclisiran

Trial Indication(s)

ASCVD

Elevated Cholesterol

Heterozygous familial hypercholesterolemia

Homozygous familial hypercholesterolemia

Protocol Number

MDCO-PCS-17-05

Protocol Title

An open-label extension trial of the Phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C

Clinical Trial Phase

Phase 3

Phase of Drug Development

Full development

**Study Start/End Dates**

Study Start Date: April 2019 (Actual)

Primary Completion Date: February 2023 (Actual)

Study Completion Date: February 2023 (Actual)

Reason for Termination (If applicable)

Not applicable

Study Design/Methodology

This study was an open label, long term extension study in subjects with atherosclerotic cardiovascular disease (ASCVD), ASCVD-risk equivalents (eg, diabetes and familial hypercholesterolemia), or heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose of LDL-C lowering therapies who have completed the inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3; NCT03060577), or any of the following Phase III lipid lowering studies: MDCO-PCS-17-03 (ORION-9; NCT03397121), MDCO-PCS-17-04 (ORION-10; NCT03399370), or MDCO-PCS-17-08 (ORION-11; NCT03400800). The End of Study (EOS) visit in the previous feeder studies was Day 1 in this extension study. The duration that each subject participated in this study was a maximum of 3 years. However, for subjects from the Study ORION-3, the Sponsor decided to end the study prior to completion of their full 3-year of participation. It is recorded in the database as discontinuation was due to Sponsor's decision. In this Phase III extension study, the same study drug of inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) was administered as a single subcutaneous (SC) dose every 180 days from the last dose in previous feeder study (except for subjects newly initiating inclisiran, who received the first two doses 90 days apart) until the end of the study. On Day 1 (EOS visit in the feeder study), subjects from the previous feeder studies received blinded study medication except subjects from Study ORION-3. Subjects who received placebo in the previous Phase III feeder study received blinded inclisiran and subjects who received inclisiran in the previous feeder study received blinded placebo at this visit, so that subjects previously on placebo received the correct dosing regime, i.e. a dose at Day 1, Day 90 and every 180-days thereafter. Subjects previously treated with inclisiran did not need a dose of inclisiran to maintain every 180-dosing regime and therefore, were given placebo in order to maintain the blinding of the feeder study. Subjects that moved over from ORION-3 received the first study medication at Day 90, as this study was already open-label. On Day 90, all subjects received inclisiran sodium 300 mg. This is 180 days after the last injection in the previous feeder study for subjects that received inclisiran and was the second dose of inclisiran for the subjects that received placebo in the feeder study. The EOS visit occurred at Day 1080. This extension study allowed subjects continued access to inclisiran treatment and allowed the collection of additional efficacy and safety data for long-term use beyond the end of the feeder studies.

Centers

268 centers in 13 countries: United States(145), Canada(8), Czechia(4), Denmark(6), Germany(9), Hungary(4), Netherlands(12), Poland(18), South Africa(12), Spain(6), Sweden(3), Ukraine(8), United Kingdom(33)

Objectives:

Primary objectives were to evaluate:

- The effect of inclisiran treatment on the proportion of subjects achieving the pre-specified LDL-C targets at the end of study (EOS)
- The safety and tolerability profile of long-term use of inclisiran

Secondary objectives were to evaluate:

- The effect of inclisiran on LDL-C levels
- The effect of inclisiran on other lipids and lipoproteins

Test Product (s), Dose(s), and Mode(s) of Administration

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) was administered as a single subcutaneous (SC) dose every 180 days from the last dose in previous feeder study (except for subjects newly initiating inclisiran, who received the first two doses 90 days apart) until the end of the study.

Statistical Methods

Study-collected data was summarized by the actual treatment groups of the feeder studies [Phase III Inclisiran-Inclisiran subjects who received inclisiran (actual treatment) in studies ORION-9/ ORION-10/ ORION-11, Phase III Placebo-Inclisiran subjects who received placebo (actual treatment) in ORION-9 ORION-10/ ORION-11 and ORION-3 Rollover] using descriptive statistics.

Analyses for the final CSR was conducted after the final database lock (DBL) of the study. The final DBL was performed after ORION-9/ ORION-10/ ORION-11 rollover subjects either completed the Day 1080 visit or discontinued early and the ORION-3 rollover subjects had completed their EOS visit ≥ 90 days after their last dosing visit.

Study Population: Key Inclusion/Exclusion Criteria

Inclusion Criteria:

1. Completion on a previously qualifying inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3), or Phase III lipid lowering ORION feeder study [MDCO-PCS-17-03 (ORION-9), MDCO-PCS-17-4 (ORION-10), or MDCO-PCS-17-08 (ORION-11)] meaning the subject received the last dose of study drug and completed the final study visit per applicable protocol.
2. On current lipid-lowering therapies (such as a statin and/or ezetimibe) from previous study with no planned medication or dose change during study participation.
3. Willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures.

Exclusion Criteria:

1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk [according to investigator's (or delegate's) judgment] if he/she participates in the clinical study.
2. An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results.
3. Severe concomitant noncardiovascular disease that carries the risk of reducing life expectancy to less than 3 years,
4. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST), elevation $>3\times$ the upper limit of normal (ULN), or total bilirubin (TBIL) elevation $>2\times$ ULN at the last recorded visit in the feeder study prior to study entry visit.
5. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least one method of acceptable effective contraception (eg, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion:
 - a. Women >2 years postmenopausal (defined as 1 year or longer since last menstrual period) and more than 55 years of age.
 - b. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.
 - c. Women who are surgically sterilized at least 3 months prior to enrollment.
6. Planned use of other investigational medicinal products other than inclisiran or devices during the course of the study.
7. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
 - a. Subjects who are unable to communicate or to cooperate with the investigator
 - b. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency)
 - c. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study)

- d. Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study
- e. Persons directly involved in the conduct of the study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Participant Flow Table

Overall Study

Arm/Group Description	Phase III Inclisiran- Inclisiran	Phase III Placebo- Inclisiran	ORION-3 Rollover	Total
	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study	
Started	1513	1478	284	3275
Safety Population	1512 ^[1]	1478	284	3274
Completed	1246	1200	0	2446
Not Completed	267	278	284	829
Sponsor's Administrative Decision	0	0	272	272
Death	80	81	4	165
Withdrew Consent	77	78	2	157

Lost to Follow-up	47	52	1	100
Adverse Event	22	23	0	45
Physician Decision	7	4	2	13
Initiation Of Protocol-Prohibited Approved PCSK9 Inhibitor	0	0	1	1
Other reasons	34	40	2	76

[1] One patient discontinued before receiving the study treatment. Hence safety population has one less patient.

Baseline Characteristics

	Phase III Inclisiran- Inclisiran	Phase III Placebo- Inclisiran	ORION-3 Rollover	Total
Arm/Group Description	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study	
Number of Participants [units: participants]	1512	1478	284	3274

Age Continuous

(units: years)

 Mean \pm Standard Deviation

	64.7 \pm 9.83	64.6 \pm 9.82	67.7 \pm 9.97	64.9 \pm 9.88
--	-----------------	-----------------	-----------------	-----------------

Sex: Female, Male

(units: participants)

Count of Participants (Not Applicable)

Female	482	476	100	1058
Male	1030	1002	184	2216

Race/Ethnicity, Customized

(units: participants)

Count of Participants (Not Applicable)

American Indian/Alaska Native	3	2	2	7
Asian	17	7	3	27
Black/African American	103	78	7	188
Native Hawaiian/Other Pacific Islander	6	4	0	10
White	1383	1387	271	3041
Missing	0	0	1	1

Primary Outcome Result(s)

Proportion of subjects achieving global lipid targets for their level of ASCVD risk

(Time Frame: From ORION-8 Day 1 to the end of study (up to 1080 days))

Phase III Inclisiran- Inclisiran	Phase III Placebo- Inclisiran	ORION-3 Rollover	Total
--	-------------------------------------	---------------------	-------

Arm/Group Description	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study	Total
Number of Participants Analyzed [units: participants]	1251	1204	276	2731
Proportion of subjects achieving global lipid targets for their level of ASCVD risk (units: Percentage of participants) Number (95% Confidence Interval)				
% of subjects Who Attain Global Lipid Targets at Day 1080 / EOS	78.18 (75.8 to 80.4)	79.07 (76.7 to 81.3)	76.81 (71.4 to 81.6)	78.43 (76.8 to 80.0)
% of ASCVD subjects Who Attain Global Lipid Targets of <70 mg/dL at Day 1080 / EOS	79.34 (76.8 to 81.7)	79.96 (77.4 to 82.4)	76.70 (70.0 to 82.5)	79.41 (77.7 to 81.1)
% of ASCVD Risk Equivalent subjects Who Attain Global Lipid Targets of <100 mg/dL at Day 1080 / EOS	72.56 (66.1 to 78.3)	74.88 (68.6 to 80.5)	77.00 (67.7 to 84.7)	74.33 (70.4 to 78.0)

Incidence of treatment-emergent adverse events (TEAEs)

(Time Frame: From ORION-8 Day 1 to the end of study (up to 1080 days))

	Phase III Inclisiran-Inclisiran	Phase III Placebo-Inclisiran	ORION-3 Rollover	Total
Arm/Group Description	Subjects who received inclisiran	subjects who received placebo	Subjects rolling over	Total

	(actual treatment) in studies ORION-9/ ORION- 10/ORION-11	(actual treatment) in ORION- 9/ORION- 10/ORION-11	from ORION-3 Phase II study	
Number of Participants Analyzed [units: participants]	1512	1478	284	3274
Incidence of treatment-emergent adverse events (TEAEs) (units: participants) Count of Participants (Not Applicable)				
Adverse events	1197 (79.17%)	1170 (79.16%)	181 (63.73%)	2548 (77.83%)
Adverse events :Treatment-related	133 (8.8%)	148 (10.01%)	16 (5.63%)	297 (9.07%)
SAEs	464 (30.69%)	482 (32.61%)	43 (15.14%)	989 (30.21%)
SAEs: Treatment-related	2 (.13%)	2 (.14%)	1 (.35%)	5 (.15%)
Fatal SAEs	80 (5.29%)	81 (5.48%)	4 (1.41%)	165 (5.04%)
Fatal SAEs: Treatment- related	0 (%)	0 (%)	0 (%)	0 (%)

Secondary Outcome Result(s)

Absolute change in LDL-C from the initial feeder study baseline

(Time Frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days))

Phase III Inclisiran- Inclisiran	Phase III Placebo- Inclisiran	ORION-3 Rollover
---	--	-----------------------------

Arm/Group Description	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study
Number of Participants Analyzed [units: participants]	1512	1478	284
Absolute change in LDL-C from the initial feeder study baseline (units: mg/dL) Mean (95% Confidence Interval)			
ORION-8 Baseline	-55.21 (-56.9 to -53.5)	0.46 (-1.4 to 2.3)	-61.58 (-66.4 to -56.8)
Day 1080 / EOS	-55.81 (-58.0 to -53.6)	-54.70 (-56.9 to -52.5)	-64.31 (-69.0 to -59.7)

Percentage change in LDL-C from the initial feeder study baseline

(Time Frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days))

Arm/Group Description	Phase III Inclisiran-Inclisiran	Phase III Placebo-Inclisiran	ORION-3 Rollover
	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study

Number of Participants

Analyzed [units: participants]	1512	1478	284
---------------------------------------	------	------	-----

Percentage change in LDL-C from the initial feeder study baseline

(units: Percentage change in LDL-C)

Mean (95% Confidence Interval)

ORION-8 Baseline	-50.02 (-51.3 to -48.8)	3.10 (1.4 to 4.9)	-48.22 (-51.2 to -45.2)
Day 1080 / EOS	-48.96 (-50.5 to -47.4)	-49.69 (-51.3 to -48.0)	-49.95 (-52.6 to -47.3)

Absolute change from the initial feeder study baseline in total cholesterol, triglycerides and HDL-C

(Time Frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days))

	Phase III Inclisiran- Inclisiran	Phase III Placebo- Inclisiran	ORION-3 Rollover
Arm/Group Description	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study
Number of Participants Analyzed [units: participants]	1512	1478	284

Absolute change from the initial feeder study baseline in total cholesterol, triglycerides and HDL-C

(units: mg/dL)

Mean (95% Confidence Interval)

ORION-8 Baseline Total Cholesterol (TC)	-59.05 (-61.0 to -57.1)	-0.07 (-2.2 to 2.1)	-63.11 (-68.3 to -57.9)
Day 1080 / EOS Total Cholesterol (TC)	-58.48 (-61.0 to -55.9)	-57.08 (-59.6 to -54.6)	-65.43 (-70.5 to -60.3)
ORION-8 Baseline Triglycerides	-21.50 (-25.1 to -17.9)	-5.74 (-9.5 to -2.0)	-14.43 (-23.7 to -5.1)
Day 1080 / EOS Triglycerides	-19.58 (-23.7 to -15.4)	-22.12 (-26.3 to -17.9)	-21.32 (-30.3 to -12.4)
ORION-8 Baseline HDL Cholesterol	3.37 (2.9 to 3.9)	0.59 (0.1 to 1.1)	3.41 (2.2 to 4.6)
Day 1080 / EOS HDL Cholesterol	3.60 (3.0 to 4.2)	4.39 (3.8 to 5.0)	5.27 (3.8 to 6.7)

Percentage change from the initial feeder study baseline in total cholesterol, triglycerides and HDL-C

(Time Frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days))

	Phase III Inclisiran- Inclisiran	Phase III Placebo- Inclisiran	ORION-3 Rollover
Arm/Group Description	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study
Number of Participants Analyzed [units: participants]	1512	1478	284

Percentage change from the initial feeder study baseline in total cholesterol, triglycerides and HDL-C

(units: Percentage change)

Mean (95% Confidence Interval)

ORION-8 Baseline Total Cholesterol (TC)	-30.64 (-31.5 to -29.7)	1.28 (0.1 to 2.4)	-29.49 (-31.6 to -27.4)
Day 1080 / EOS Total Cholesterol (TC)	-29.34 (-30.5 to -28.2)	-29.53 (-30.7 to -28.4)	-30.44 (-32.4 to -28.5)
ORION-8 Baseline Triglycerides	-7.84 (-10.0 to -5.7)	3.03 (0.8 to 5.2)	-0.20 (-7.6 to 7.2)
Day 1080 / EOS Triglycerides	-3.90 (-6.5 to -1.3)	-6.85 (-9.2 to -4.5)	-3.18 (-9.2 to 2.8)
ORION-8 Baseline HDL Cholesterol	9.28 (8.2 to 10.4)	3.48 (2.4 to 4.6)	8.13 (5.7 to 10.5)
Day 1080 / EOS HDL Cholesterol	9.91 (8.7 to 11.2)	11.75 (10.3 to 13.2)	12.16 (9.3 to 15.0)

Other Pre-Specified Outcome Result(s)

Post-Hoc Outcome Result(s)

Safety Results

All-Cause Mortality

	Phase III Inclisiran- Inclisiran N = 1512	Phase III Placebo- Inclisiran N = 1478	ORION-3 Rollover N = 284	Total N = 3274
Arm/Group Description	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study	Total
Total participants affected	80 (5.29%)	81 (5.48%)	4 (1.41%)	165 (5.04%)

Serious Adverse Events

Time Frame Adverse events were reported from the start of study in ORION-8 until end of study treatment plus 90 days post treatment, up to a maximum duration of 1080 days.

Additional Description Adverse Events are assessed in the safety population.

Source Vocabulary for Table Default MedDRA (25.1)

Assessment Type for Table Default Systematic Assessment

	Phase III Inclisiran- Inclisiran N = 1512	Phase III Placebo- Inclisiran N = 1478	ORION-3 Rollover N = 284	Total N = 3274
Arm/Group Description	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study	Total
Total participants affected	464 (30.69%)	482 (32.61%)	43 (15.14%)	989 (30.21%)
Blood and lymphatic system disorders				
Anaemia	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Anaemia macrocytic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood loss anaemia	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Deficiency anaemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Iron deficiency anaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Lymphadenitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Microcytic anaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Pancytopenia	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Cardiac disorders				
Acute coronary syndrome	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Acute left ventricular failure	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Acute myocardial infarction	17 (1.12%)	24 (1.62%)	3 (1.06%)	44 (1.34%)
Angina pectoris	21 (1.39%)	20 (1.35%)	2 (0.70%)	43 (1.31%)
Angina unstable	12 (0.79%)	18 (1.22%)	2 (0.70%)	32 (0.98%)
Aortic valve calcification	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Aortic valve stenosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Arrhythmia	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Arrhythmic storm	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Arteriosclerosis coronary artery	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Atrial fibrillation	17 (1.12%)	15 (1.01%)	3 (1.06%)	35 (1.07%)
Atrial flutter	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Atrioventricular block complete	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Atrioventricular block second degree	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Bradycardia	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)
Cardiac arrest	3 (0.20%)	6 (0.41%)	0 (0.00%)	9 (0.27%)
Cardiac disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cardiac failure	10 (0.66%)	15 (1.01%)	1 (0.35%)	26 (0.79%)
Cardiac failure acute	4 (0.26%)	3 (0.20%)	0 (0.00%)	7 (0.21%)
Cardiac failure chronic	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)

Cardiac failure congestive	15 (0.99%)	13 (0.88%)	1 (0.35%)	29 (0.89%)
Cardiogenic shock	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cardiomyopathy	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Cardiorenal syndrome	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cardio-respiratory arrest	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Cardiovascular insufficiency	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Chronic coronary syndrome	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Chronic left ventricular failure	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Congestive cardiomyopathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Coronary artery disease	36 (2.38%)	26 (1.76%)	2 (0.70%)	64 (1.95%)
Coronary artery occlusion	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Coronary artery stenosis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Diastolic dysfunction	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ischaemic cardiomyopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Left ventricular dysfunction	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Left ventricular failure	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Mitral valve incompetence	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Myocardial infarction	12 (0.79%)	19 (1.29%)	2 (0.70%)	33 (1.01%)
Myocardial ischaemia	7 (0.46%)	8 (0.54%)	0 (0.00%)	15 (0.46%)
Nodal arrhythmia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Pericarditis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Prinzmetal angina	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Sinus bradycardia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Sinus node dysfunction	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Sinus tachycardia	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Supraventricular tachycardia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Ventricular extrasystoles	3 (0.20%)	0 (0.00%)	1 (0.35%)	4 (0.12%)
Ventricular fibrillation	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Ventricular hypokinesia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ventricular tachycardia	4 (0.26%)	6 (0.41%)	0 (0.00%)	10 (0.31%)
Congenital, familial and genetic disorders				
Hydrocele	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ear and labyrinth disorders				
Ear canal stenosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Meniere's disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Otosclerosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Vertigo	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Vestibular disorder	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Endocrine disorders				
Goitre	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hyperparathyroidism primary	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hypothyroidism	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Thyroiditis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Eye disorders

Cataract	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Diplopia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Retinal detachment	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Retinal vein thrombosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Gastrointestinal disorders

Abdominal fat apron	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Abdominal hernia	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Abdominal pain	6 (0.40%)	2 (0.14%)	0 (0.00%)	8 (0.24%)
Abdominal pain lower	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Abdominal pain upper	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Anal haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ascites	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Colitis	5 (0.33%)	0 (0.00%)	0 (0.00%)	5 (0.15%)
Colitis ischaemic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Constipation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Diarrhoea	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Diverticulum	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Diverticulum intestinal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Duodenogastric reflux	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dyspepsia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Enteritis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Faecaloma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gastric fistula	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastric haemorrhage	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Gastric ulcer	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastric volvulus	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastritis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastrointestinal haemorrhage	5 (0.33%)	4 (0.27%)	0 (0.00%)	9 (0.27%)
Gastrooesophageal reflux disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Haemorrhoids	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ileus	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Incarcerated inguinal hernia	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Inguinal hernia	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Intestinal atony	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Intestinal ischaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Intestinal obstruction	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Intestinal polyp	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Large intestinal haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Large intestinal obstruction	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Large intestine polyp	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Nausea	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Obstructive pancreatitis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Oesophageal dysplasia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Oesophageal mucosal tear	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pancreatic cyst	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pancreatitis	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)

Pancreatitis acute	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Pancreatitis chronic	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Proctitis ulcerative	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pylorospasm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Rectal haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Rectal prolapse	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Retroperitoneal haematoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Retroperitoneal haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Salivary duct obstruction	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Small intestinal obstruction	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Small intestinal ulcer haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Terminal ileitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Umbilical hernia	1 (0.07%)	4 (0.27%)	0 (0.00%)	5 (0.15%)
Upper gastrointestinal haemorrhage	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Vomiting	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
General disorders and administration site conditions				
Asthenia	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Chest discomfort	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Chest pain	6 (0.40%)	8 (0.54%)	3 (1.06%)	17 (0.52%)
Death	12 (0.79%)	19 (1.29%)	2 (0.70%)	33 (1.01%)
Exercise tolerance decreased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Face oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Multiple organ dysfunction syndrome	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Non-cardiac chest pain	10 (0.66%)	10 (0.68%)	0 (0.00%)	20 (0.61%)
Oedema peripheral	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Organ failure	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pyrexia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sudden cardiac death	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Swelling face	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vascular stent occlusion	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vascular stent stenosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Hepatobiliary disorders				
Bile duct stenosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Biliary colic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cholecystitis	2 (0.13%)	4 (0.27%)	1 (0.35%)	7 (0.21%)
Cholecystitis acute	3 (0.20%)	6 (0.41%)	0 (0.00%)	9 (0.27%)
Cholelithiasis	6 (0.40%)	2 (0.14%)	0 (0.00%)	8 (0.24%)
Cirrhosis alcoholic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gallbladder rupture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hepatic fibrosis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Hepatomegaly	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ischaemic hepatitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Immune system disorders				
Hypersensitivity	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Immunisation reaction	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Sarcoidosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Infections and infestations				
Abscess limb	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Anal abscess	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Appendicitis	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Appendicitis perforated	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Arthritis bacterial	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Atypical pneumonia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Bacteraemia	1 (0.07%)	1 (0.07%)	1 (0.35%)	3 (0.09%)
Bacterial colitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bacterial infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bronchitis	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Cellulitis	7 (0.46%)	7 (0.47%)	1 (0.35%)	15 (0.46%)
Cholecystitis infective	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Chronic sinusitis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
COVID-19	21 (1.39%)	28 (1.89%)	0 (0.00%)	49 (1.50%)
COVID-19 pneumonia	14 (0.93%)	21 (1.42%)	0 (0.00%)	35 (1.07%)
Device related infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Diabetic foot infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Diverticulitis	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Empyema	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Endocarditis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Enterobacter infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Enterobacter pneumonia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Enterococcal bacteraemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Epstein-Barr virus infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gangrene	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Gastroenteritis	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Gastroenteritis salmonella	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastroenteritis viral	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Herpes zoster meningoencephalitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Implant site infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Infected bite	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Infected skin ulcer	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Infective exacerbation of chronic obstructive airways disease	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Influenza	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Intervertebral discitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Labyrinthitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Laryngitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Localised infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Lower respiratory tract infection	1 (0.07%)	4 (0.27%)	0 (0.00%)	5 (0.15%)
Neuroborreliosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Osteomyelitis	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)
Osteomyelitis chronic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Peritonitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Pneumonia	16 (1.06%)	17 (1.15%)	2 (0.70%)	35 (1.07%)
Pneumonia bacterial	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Pneumonia viral	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Post procedural infection	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Post-acute COVID-19 syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Postoperative wound infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pyelitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pyelonephritis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Sepsis	4 (0.26%)	8 (0.54%)	3 (1.06%)	15 (0.46%)
Septic shock	1 (0.07%)	5 (0.34%)	0 (0.00%)	6 (0.18%)
Sinusitis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Skin infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Streptococcal urinary tract infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Subcutaneous abscess	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Tooth abscess	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Urinary tract infection	9 (0.60%)	5 (0.34%)	0 (0.00%)	14 (0.43%)
Urosepsis	3 (0.20%)	0 (0.00%)	1 (0.35%)	4 (0.12%)
Viraemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Viral infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Wound infection	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Wound sepsis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Injury, poisoning and procedural complications				
Acetabulum fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Alcohol poisoning	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Animal bite	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ankle fracture	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)
Aortic restenosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Back injury	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Concussion	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Fall	6 (0.40%)	0 (0.00%)	0 (0.00%)	6 (0.18%)
Femoral neck fracture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Femur fracture	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Fibula fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Fracture displacement	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Fractured sacrum	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Heat stroke	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hip fracture	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Incisional hernia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Joint dislocation	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Joint injury	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ligament rupture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Limb injury	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Lower limb fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lumbar vertebral fracture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Overdose	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Patella fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pelvic fracture	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Periprosthetic fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Post procedural haematoma	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Postoperative wound complication	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Procedural haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Procedural hypotension	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Radius fracture	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Rib fracture	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Road traffic accident	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Skin laceration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Spinal compression fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Sternal fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Stomal hernia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Subdural haematoma	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Subdural haemorrhage	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Tendon rupture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Thermal burn	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Thoracic vertebral fracture	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Tibia fracture	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Toxicity to various agents	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Traumatic fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Traumatic haemothorax	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Upper limb fracture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Vascular access site haematoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Vascular graft occlusion	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Wound dehiscence	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Investigations

Anticoagulation drug level above therapeutic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood creatinine increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Haemoglobin decreased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hepatic enzyme increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Myocardial necrosis marker increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Oxygen saturation decreased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Prostatic specific antigen increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Troponin increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Troponin T increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Metabolism and nutrition disorders

Cachexia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Dehydration	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Diabetes mellitus	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Diabetes mellitus inadequate control	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Diabetic ketoacidosis	4 (0.26%)	0 (0.00%)	0 (0.00%)	4 (0.12%)
Gout	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)

Hypercalcaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hyperglycaemia	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Hyperglycaemic hyperosmolar nonketotic syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hyperkalaemia	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Hypertriglyceridaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hypervolaemia	0 (0.00%)	4 (0.27%)	0 (0.00%)	4 (0.12%)
Hypoglycaemia	4 (0.26%)	3 (0.20%)	0 (0.00%)	7 (0.21%)
Hypokalaemia	3 (0.20%)	0 (0.00%)	1 (0.35%)	4 (0.12%)
Hyponatraemia	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Hypovolaemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Iron deficiency	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Musculoskeletal and connective tissue disorders				
Ankylosing spondylitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Arthralgia	2 (0.13%)	5 (0.34%)	0 (0.00%)	7 (0.21%)
Arthritis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Back pain	8 (0.53%)	0 (0.00%)	0 (0.00%)	8 (0.24%)
Bursitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Foot deformity	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Haematoma muscle	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Intervertebral disc degeneration	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Intervertebral disc disorder	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)

Intervertebral disc protrusion	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Joint instability	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lumbar spinal stenosis	5 (0.33%)	3 (0.20%)	1 (0.35%)	9 (0.27%)
Mobility decreased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Muscular weakness	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Musculoskeletal disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Musculoskeletal pain	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Musculoskeletal stiffness	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Neck pain	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Osteoarthritis	16 (1.06%)	20 (1.35%)	0 (0.00%)	36 (1.10%)
Pain in extremity	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Rhabdomyolysis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Rheumatoid arthritis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Rotator cuff syndrome	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Scoliosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Spinal osteoarthritis	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Spinal pain	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Spinal stenosis	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Spinal synovial cyst	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Spondylolisthesis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Systemic lupus erythematosus	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Tenosynovitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

**Neoplasms benign,
malignant and**

**unspecified (incl cysts
and polyps)**

Acute myeloid leukaemia	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Adenocarcinoma metastatic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Adenocarcinoma of colon	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Anaplastic thyroid cancer	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Basal cell carcinoma	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Benign lung neoplasm	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Benign neoplasm of thyroid gland	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bladder cancer	5 (0.33%)	2 (0.14%)	1 (0.35%)	8 (0.24%)
Bladder cancer recurrent	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bladder neoplasm	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Bladder transitional cell carcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bowen's disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Breast cancer	2 (0.13%)	5 (0.34%)	1 (0.35%)	8 (0.24%)
Breast cancer metastatic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Brenner tumour	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bronchial carcinoma	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Chronic lymphocytic leukaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Clear cell renal cell carcinoma	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Colon cancer	2 (0.13%)	5 (0.34%)	0 (0.00%)	7 (0.21%)

Colon neoplasm	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Colorectal adenocarcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Colorectal adenoma	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Colorectal cancer	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Diffuse large B-cell lymphoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastrointestinal carcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gastrointestinal neoplasm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gastrointestinal stromal tumour	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastrointestinal tract adenoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Glioblastoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hepatic cancer	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hepatocellular carcinoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Invasive ductal breast carcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Laryngeal papilloma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Leukaemia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Lip and/or oral cavity cancer	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lip neoplasm malignant stage unspecified	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lip squamous cell carcinoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lung adenocarcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Lung adenocarcinoma stage IV	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Lung cancer metastatic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Lung carcinoma cell type unspecified stage IV	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lung neoplasm	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lung neoplasm malignant	7 (0.46%)	4 (0.27%)	0 (0.00%)	11 (0.34%)
Lung squamous cell carcinoma metastatic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lymphoma	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Malignant glioma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Malignant mediastinal neoplasm	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Malignant melanoma	3 (0.20%)	2 (0.14%)	0 (0.00%)	5 (0.15%)
Malignant melanoma in situ	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Malignant pleural effusion	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Mantle cell lymphoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Metastases to bone	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Metastases to central nervous system	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Metastases to liver	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Metastases to lung	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Metastases to lymph nodes	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Metastatic malignant melanoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Metastatic renal cell carcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Neoplasm prostate	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Neuroendocrine carcinoma metastatic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Non-Hodgkin's lymphoma stage III	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Non-small cell lung cancer	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Non-small cell lung cancer metastatic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Oesophageal carcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Oesophageal neoplasm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Oncocytoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ovarian adenoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ovarian cancer	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Ovarian cancer metastatic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ovarian epithelial cancer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pancreatic carcinoma	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Pancreatic carcinoma metastatic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pancreatic neoplasm	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Paraneoplastic syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Parathyroid tumour benign	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Plasma cell myeloma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Prostate cancer	8 (0.53%)	7 (0.47%)	0 (0.00%)	15 (0.46%)

Prostate cancer metastatic	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Rectal cancer	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Renal cell carcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sarcoma uterus	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Small cell lung cancer	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Small cell lung cancer metastatic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Squamous cell carcinoma	2 (0.13%)	2 (0.14%)	1 (0.35%)	5 (0.15%)
Squamous cell carcinoma of lung	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Squamous cell carcinoma of skin	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Squamous cell carcinoma of the oral cavity	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Transitional cell carcinoma	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Transitional cell carcinoma metastatic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Triple negative breast cancer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ureteric cancer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Uterine leiomyoma	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Nervous system disorders				
Aphasia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Basal ganglia haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Bell's palsy	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Carotid arteriosclerosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Carotid artery disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Carotid artery stenosis	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Carpal tunnel syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cauda equina syndrome	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Cerebellar haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cerebral haemorrhage	1 (0.07%)	1 (0.07%)	1 (0.35%)	3 (0.09%)
Cerebral infarction	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Cerebral ischaemia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Cerebrovascular accident	8 (0.53%)	4 (0.27%)	2 (0.70%)	14 (0.43%)
Cerebrovascular disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cervical cord compression	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cortical laminar necrosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dementia Alzheimer's type	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dizziness	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Embolic stroke	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Encephalopathy	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Epilepsy	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Haemorrhage intracranial	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Intracranial mass	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ischaemic cerebral infarction	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Ischaemic stroke	16 (1.06%)	10 (0.68%)	0 (0.00%)	26 (0.79%)
Lacunar infarction	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Lacunar stroke	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Loss of consciousness	4 (0.26%)	0 (0.00%)	0 (0.00%)	4 (0.12%)
Lumbar radiculopathy	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Metabolic encephalopathy	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Migraine	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Myelopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nervous system disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Optic neuritis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Paralysis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Parkinson's disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Polyneuropathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Presyncope	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Sciatica	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Subarachnoid haemorrhage	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Syncope	11 (0.73%)	6 (0.41%)	1 (0.35%)	18 (0.55%)
Thalamus haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Transient ischaemic attack	5 (0.33%)	7 (0.47%)	1 (0.35%)	13 (0.40%)
Vascular encephalopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Vasogenic cerebral oedema	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Product issues

Device dislocation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Device loosening	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Device malfunction	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Device occlusion	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Psychiatric disorders				
Completed suicide	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Confusional state	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Conversion disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Depression	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Generalised anxiety disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Major depression	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Mental status changes	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Psychotic disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Suicidal ideation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Renal and urinary disorders				
Acute kidney injury	16 (1.06%)	12 (0.81%)	1 (0.35%)	29 (0.89%)
Chronic kidney disease	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
End stage renal disease	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Glomerulonephritis chronic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Glomerulonephritis membranous	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Haematuria	4 (0.26%)	0 (0.00%)	0 (0.00%)	4 (0.12%)
Hydronephrosis	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Nephrolithiasis	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)

Neurogenic bladder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Renal failure	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Renal haemorrhage	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Renal impairment	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Renal mass	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ureteric obstruction	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ureterolithiasis	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Urethral stenosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Urinary retention	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Urinary tract obstruction	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Reproductive system and breast disorders				
Benign prostatic hyperplasia	7 (0.46%)	2 (0.14%)	0 (0.00%)	9 (0.27%)
Breast necrosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cystocele	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Perineal fistula	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Postmenopausal haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Prostatitis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Uterine prolapse	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Respiratory, thoracic and mediastinal disorders				
Acute pulmonary oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Acute respiratory failure	9 (0.60%)	17 (1.15%)	2 (0.70%)	28 (0.86%)
Asthma	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)

Bronchiectasis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Chronic obstructive pulmonary disease	8 (0.53%)	9 (0.61%)	0 (0.00%)	17 (0.52%)
Chronic respiratory failure	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dyspnoea	6 (0.40%)	8 (0.54%)	2 (0.70%)	16 (0.49%)
Dyspnoea exertional	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Hypoxia	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Laryngeal oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nasal disorder	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Obstructive sleep apnoea syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pleural effusion	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Pneumonitis aspiration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pneumothorax	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Pneumothorax spontaneous	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pulmonary embolism	8 (0.53%)	6 (0.41%)	0 (0.00%)	14 (0.43%)
Pulmonary hypertension	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pulmonary oedema	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Pulmonary sarcoidosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Respiratory failure	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Skin and subcutaneous tissue disorders				
Diabetic foot	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Diabetic ulcer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Rash	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Reactive perforating collagenosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Skin ulcer	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vascular disorders				
Aneurysm	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Aortic aneurysm	5 (0.33%)	7 (0.47%)	0 (0.00%)	12 (0.37%)
Aortic dissection	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Aortic occlusion	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Aortic stenosis	3 (0.20%)	6 (0.41%)	0 (0.00%)	9 (0.27%)
Arterial stenosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Arteriosclerosis	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Circulatory collapse	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Deep vein thrombosis	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Embolism venous	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Essential hypertension	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Extremity necrosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Granulomatosis with polyangiitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Haematoma	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Hypertension	3 (0.20%)	2 (0.14%)	1 (0.35%)	6 (0.18%)
Hypertensive crisis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hypertensive emergency	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hypertensive urgency	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Hypotension	4 (0.26%)	1 (0.07%)	1 (0.35%)	6 (0.18%)
Intermittent claudication	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)

Labile hypertension	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Leriche syndrome	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Penetrating aortic ulcer	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Peripheral arterial occlusive disease	5 (0.33%)	8 (0.54%)	0 (0.00%)	13 (0.40%)
Peripheral artery aneurysm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Peripheral artery occlusion	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Peripheral artery stenosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Peripheral embolism	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Peripheral ischaemia	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Peripheral vascular disorder	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Varicose vein	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Other (Not Including Serious) Adverse Events

Time Frame	Adverse events were reported from the start of study in ORION-8 until end of study treatment plus 90 days post treatment, up to a maximum duration of 1080 days.
Additional Description	Adverse Events are assessed in the safety population.
Source Vocabulary for Table Default	MedDRA (25.1)
Assessment Type for Table Default	Systematic Assessment
Frequent Event Reporting Threshold	0%

	Phase III Inclisiran- Inclisiran N = 1512	Phase III Placebo- Inclisiran N = 1478	ORION-3 Rollover N = 284	Total N = 3274
Arm/Group Description	Subjects who received inclisiran (actual treatment) in studies ORION-9/ORION-10/ORION-11	subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11	Subjects rolling over from ORION-3 Phase II study	Total
Total participants affected	1110 (73.41%)	1073 (72.60%)	169 (59.51%)	2352 (71.84%)
Blood and lymphatic system disorders				
Anaemia	45 (2.98%)	33 (2.23%)	2 (0.70%)	80 (2.44%)
Anaemia macrocytic	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Anaemia megaloblastic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Anaemia vitamin B12 deficiency	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bicytopenia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood loss anaemia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Bone marrow oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Coagulopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cytopenia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eosinophilia	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Haemolytic anaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hilar lymphadenopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hypochromic anaemia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)

Increased tendency to bruise	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Iron deficiency anaemia	10 (0.66%)	4 (0.27%)	0 (0.00%)	14 (0.43%)
Leukocytosis	8 (0.53%)	4 (0.27%)	0 (0.00%)	12 (0.37%)
Leukopenia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lymph node fibrosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Lymphadenopathy	2 (0.13%)	3 (0.20%)	1 (0.35%)	6 (0.18%)
Macrocytosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Microcytic anaemia	3 (0.20%)	5 (0.34%)	1 (0.35%)	9 (0.27%)
Monoclonal B-cell lymphocytosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nephrogenic anaemia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Neutropenia	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Normochromic normocytic anaemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Normocytic anaemia	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Pancytopenia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Polycythaemia	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Splenomegaly	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Thrombocytopenia	0 (0.00%)	8 (0.54%)	0 (0.00%)	8 (0.24%)
Thrombocytosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cardiac disorders				
Acute myocardial infarction	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Angina pectoris	24 (1.59%)	32 (2.17%)	2 (0.70%)	58 (1.77%)
Angina unstable	4 (0.26%)	3 (0.20%)	0 (0.00%)	7 (0.21%)
Aortic valve incompetence	4 (0.26%)	4 (0.27%)	0 (0.00%)	8 (0.24%)

Aortic valve sclerosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Aortic valve stenosis	2 (0.13%)	5 (0.34%)	0 (0.00%)	7 (0.21%)
Arrhythmia	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Arrhythmia supraventricular	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Arteriosclerosis coronary artery	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Atrial enlargement	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Atrial fibrillation	40 (2.65%)	36 (2.44%)	4 (1.41%)	80 (2.44%)
Atrial flutter	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Atrial tachycardia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Atrial thrombosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Atrioventricular block	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Atrioventricular block complete	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Atrioventricular block first degree	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Atrioventricular block second degree	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Bradycardia	12 (0.79%)	13 (0.88%)	1 (0.35%)	26 (0.79%)
Bundle branch block	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bundle branch block left	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Bundle branch block right	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Cardiac amyloidosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cardiac aneurysm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cardiac disorder	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Cardiac failure	15 (0.99%)	19 (1.29%)	0 (0.00%)	34 (1.04%)
Cardiac failure acute	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Cardiac failure chronic	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Cardiac failure congestive	15 (0.99%)	11 (0.74%)	0 (0.00%)	26 (0.79%)
Cardiac flutter	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Cardiac hypertrophy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cardiac perfusion defect	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Cardiac sarcoidosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cardiac valve disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cardiac ventricular thrombosis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Cardiogenic shock	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cardiomegaly	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Cardiomyopathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cardiorenal syndrome	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Cardiovascular disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Chronic left ventricular failure	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Chronotropic incompetence	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Conduction disorder	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Congestive cardiomyopathy	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Coronary artery disease	17 (1.12%)	24 (1.62%)	0 (0.00%)	41 (1.25%)
Coronary artery occlusion	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Coronary artery stenosis	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Diastolic dysfunction	1 (0.07%)	4 (0.27%)	0 (0.00%)	5 (0.15%)
Dressler's syndrome	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Extrasystoles	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Heart valve incompetence	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Hypertensive cardiomyopathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hypertensive heart disease	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ischaemic cardiomyopathy	1 (0.07%)	4 (0.27%)	0 (0.00%)	5 (0.15%)
Left atrial enlargement	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Left ventricular dysfunction	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Left ventricular enlargement	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Left ventricular failure	1 (0.07%)	2 (0.14%)	1 (0.35%)	4 (0.12%)
Left ventricular hypertrophy	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Mitral valve calcification	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Mitral valve incompetence	11 (0.73%)	7 (0.47%)	1 (0.35%)	19 (0.58%)
Mitral valve prolapse	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Mitral valve stenosis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Myocardial ischaemia	4 (0.26%)	5 (0.34%)	0 (0.00%)	9 (0.27%)
Palpitations	21 (1.39%)	8 (0.54%)	1 (0.35%)	30 (0.92%)
Pericardial effusion	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Pericarditis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Prinzmetal angina	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pulmonary valve incompetence	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Right atrial dilatation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Sinus arrhythmia	0 (0.00%)	2 (0.14%)	1 (0.35%)	3 (0.09%)
Sinus bradycardia	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Sinus node dysfunction	4 (0.26%)	4 (0.27%)	0 (0.00%)	8 (0.24%)
Sinus tachycardia	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)

Supraventricular extrasystoles	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Supraventricular tachycardia	2 (0.13%)	8 (0.54%)	0 (0.00%)	10 (0.31%)
Systolic dysfunction	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Tachycardia	7 (0.46%)	6 (0.41%)	1 (0.35%)	14 (0.43%)
Tachycardia paroxysmal	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Tricuspid valve incompetence	6 (0.40%)	4 (0.27%)	1 (0.35%)	11 (0.34%)
Ventricular arrhythmia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Ventricular dysfunction	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Ventricular extrasystoles	9 (0.60%)	3 (0.20%)	1 (0.35%)	13 (0.40%)
Ventricular tachycardia	5 (0.33%)	9 (0.61%)	0 (0.00%)	14 (0.43%)
Congenital, familial and genetic disorders				
Adenomatous polyposis coli	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Apolipoprotein E e4 gene carrier	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Atrial septal defect	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Congenital cystic kidney disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Developmental hip dysplasia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Genetic polymorphism	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hydrocele	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Phimosis	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
SF3B1 gene mutation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Ear and labyrinth disorders

Cerumen impaction	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Conductive deafness	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Deafness	4 (0.26%)	1 (0.07%)	1 (0.35%)	6 (0.18%)
Deafness bilateral	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Deafness neurosensory	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Deafness unilateral	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Ear canal stenosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ear haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ear pain	9 (0.60%)	3 (0.20%)	0 (0.00%)	12 (0.37%)
Ear pruritus	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Eustachian tube dysfunction	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Excessive cerumen production	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Haematotympanum	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hypoacusis	0 (0.00%)	3 (0.20%)	1 (0.35%)	4 (0.12%)
Mastoid disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Meniere's disease	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Otolithiasis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Otorrhoea	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sudden hearing loss	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Tinnitus	3 (0.20%)	10 (0.68%)	0 (0.00%)	13 (0.40%)
Vertigo	15 (0.99%)	14 (0.95%)	4 (1.41%)	33 (1.01%)
Vertigo positional	4 (0.26%)	0 (0.00%)	0 (0.00%)	4 (0.12%)

Endocrine disorders

Adrenal mass	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Autoimmune thyroiditis	1 (0.07%)	4 (0.27%)	0 (0.00%)	5 (0.15%)
Goitre	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)
Hyperparathyroidism	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Hyperparathyroidism primary	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hyperprolactinaemia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Hyperthyroidism	6 (0.40%)	5 (0.34%)	0 (0.00%)	11 (0.34%)
Hypogonadism	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Hypothyroidism	10 (0.66%)	10 (0.68%)	2 (0.70%)	22 (0.67%)
Inappropriate antidiuretic hormone secretion	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Thyroid calcification	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Thyroid mass	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)

Eye disorders

Age-related macular degeneration	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Amaurosis fugax	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blepharitis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Blepharospasm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Blindness	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Cataract	40 (2.65%)	23 (1.56%)	5 (1.76%)	68 (2.08%)
Chalazion	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Choroidal neovascularisation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Conjunctival haemorrhage	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Conjunctivitis allergic	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Corneal degeneration	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Corneal erosion	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Dermatochalasis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Diabetic retinopathy	1 (0.07%)	3 (0.20%)	4 (1.41%)	8 (0.24%)
Diplopia	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Dry eye	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Ectropion	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Epiretinal membrane	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Exfoliation syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Eye discharge	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eye haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Eye irritation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eye pain	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eye pruritus	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eye swelling	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eyelid cyst	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Eyelid ptosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Glaucoma	5 (0.33%)	7 (0.47%)	1 (0.35%)	13 (0.40%)
Iridocyclitis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Iritis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Keratitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lacrimation increased	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Macular degeneration	7 (0.46%)	1 (0.07%)	1 (0.35%)	9 (0.27%)
Macular oedema	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)

Neovascular age-related macular degeneration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Non-proliferative retinopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ocular hypertension	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Periorbital swelling	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Posterior capsule opacification	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Retinal artery embolism	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Retinal artery occlusion	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Retinal detachment	2 (0.13%)	1 (0.07%)	1 (0.35%)	4 (0.12%)
Retinal haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Retinal ischaemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Retinal vascular thrombosis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Retinal vein occlusion	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Retinopathy	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Retinopathy hypertensive	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Swelling of eyelid	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ulcerative keratitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vision blurred	3 (0.20%)	4 (0.27%)	1 (0.35%)	8 (0.24%)
Visual acuity reduced	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Visual impairment	5 (0.33%)	4 (0.27%)	1 (0.35%)	10 (0.31%)
Vitreous detachment	1 (0.07%)	1 (0.07%)	1 (0.35%)	3 (0.09%)
Vitreous floaters	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Vitreous haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vitreous opacities	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Gastrointestinal disorders

Abdominal discomfort	0 (0.00%)	7 (0.47%)	1 (0.35%)	8 (0.24%)
Abdominal distension	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Abdominal hernia	2 (0.13%)	1 (0.07%)	1 (0.35%)	4 (0.12%)
Abdominal mass	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Abdominal pain	15 (0.99%)	16 (1.08%)	3 (1.06%)	34 (1.04%)
Abdominal pain lower	3 (0.20%)	2 (0.14%)	1 (0.35%)	6 (0.18%)
Abdominal pain upper	6 (0.40%)	11 (0.74%)	3 (1.06%)	20 (0.61%)
Abdominal wall haematoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Acquired oesophageal web	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Anal fissure	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Anal incontinence	0 (0.00%)	0 (0.00%)	2 (0.70%)	2 (0.06%)
Anal prolapse	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Anal skin tags	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Anorectal discomfort	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ascites	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Barrett's oesophagus	1 (0.07%)	2 (0.14%)	1 (0.35%)	4 (0.12%)
Change of bowel habit	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Chronic gastritis	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Colitis	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Colitis microscopic	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Colitis ulcerative	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Constipation	22 (1.46%)	25 (1.69%)	2 (0.70%)	49 (1.50%)
Crohn's disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Defaecation disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Dental caries	5 (0.33%)	4 (0.27%)	0 (0.00%)	9 (0.27%)
Diarrhoea	41 (2.71%)	31 (2.10%)	4 (1.41%)	76 (2.32%)
Diarrhoea haemorrhagic	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Diverticulitis oesophageal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Diverticulum	5 (0.33%)	4 (0.27%)	0 (0.00%)	9 (0.27%)
Diverticulum intestinal	6 (0.40%)	10 (0.68%)	0 (0.00%)	16 (0.49%)
Dry mouth	4 (0.26%)	0 (0.00%)	0 (0.00%)	4 (0.12%)
Duodenal polyp	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Duodenal ulcer	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Duodenitis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Duodenogastric reflux	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dyspepsia	8 (0.53%)	9 (0.61%)	1 (0.35%)	18 (0.55%)
Dysphagia	11 (0.73%)	5 (0.34%)	1 (0.35%)	17 (0.52%)
Enteritis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eosinophilic oesophagitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Epigastric discomfort	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Erosive duodenitis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Eructation	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Faeces discoloured	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Faeces soft	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Flatulence	4 (0.26%)	7 (0.47%)	0 (0.00%)	11 (0.34%)
Food poisoning	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Frequent bowel movements	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gastric antral vascular ectasia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Gastric disorder	1 (0.07%)	2 (0.14%)	1 (0.35%)	4 (0.12%)
Gastric mucosa erythema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gastric ulcer	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Gastritis	12 (0.79%)	13 (0.88%)	3 (1.06%)	28 (0.86%)
Gastritis erosive	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Gastrointestinal haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastrointestinal pain	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gastrooesophageal reflux disease	16 (1.06%)	23 (1.56%)	5 (1.76%)	44 (1.34%)
Haematemesis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Haematochezia	4 (0.26%)	3 (0.20%)	0 (0.00%)	7 (0.21%)
Haemorrhoids	9 (0.60%)	10 (0.68%)	0 (0.00%)	19 (0.58%)
Hiatus hernia	7 (0.46%)	10 (0.68%)	2 (0.70%)	19 (0.58%)
Ileus	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Ileus paralytic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Inflammatory bowel disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Inguinal hernia	5 (0.33%)	7 (0.47%)	1 (0.35%)	13 (0.40%)
Intestinal ischaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Intestinal polyp	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Irritable bowel syndrome	2 (0.13%)	2 (0.14%)	1 (0.35%)	5 (0.15%)
Large intestine polyp	10 (0.66%)	7 (0.47%)	0 (0.00%)	17 (0.52%)
Lip swelling	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Melaena	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Mouth ulceration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nausea	23 (1.52%)	17 (1.15%)	1 (0.35%)	41 (1.25%)

Odynophagia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Oesophageal stenosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Oesophagitis	5 (0.33%)	3 (0.20%)	0 (0.00%)	8 (0.24%)
Pancreatic cyst	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Pancreatic duct dilatation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pancreatic failure	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pancreatic steatosis	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Pancreatitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pancreatitis acute	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pancreatitis chronic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Peptic ulcer	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Peritoneal adhesions	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pneumoperitoneum	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Proctalgia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Proctitis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Rectal discharge	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Rectal haemorrhage	2 (0.13%)	3 (0.20%)	2 (0.70%)	7 (0.21%)
Rectal polyp	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Rectal prolapse	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Regurgitation	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Retroperitoneal haematoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Salivary gland enlargement	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Salivary gland mass	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Stomatitis	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Tongue cyst	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Tongue ulceration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Tooth impacted	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Toothache	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Umbilical hernia	5 (0.33%)	5 (0.34%)	0 (0.00%)	10 (0.31%)
Vomiting	16 (1.06%)	9 (0.61%)	3 (1.06%)	28 (0.86%)
General disorders and administration site conditions				
Adverse drug reaction	1 (0.07%)	3 (0.20%)	1 (0.35%)	5 (0.15%)
Application site rash	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Asthenia	12 (0.79%)	8 (0.54%)	0 (0.00%)	20 (0.61%)
Calcinosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Chest discomfort	8 (0.53%)	5 (0.34%)	3 (1.06%)	16 (0.49%)
Chest pain	16 (1.06%)	15 (1.01%)	5 (1.76%)	36 (1.10%)
Chills	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Crepitations	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cyst	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Drug intolerance	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Exercise tolerance decreased	6 (0.40%)	2 (0.14%)	0 (0.00%)	8 (0.24%)
Eye complication associated with device	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Facial pain	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Fatigue	27 (1.79%)	22 (1.49%)	4 (1.41%)	53 (1.62%)
Feeling abnormal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gait disturbance	2 (0.13%)	4 (0.27%)	1 (0.35%)	7 (0.21%)
Generalised oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Hernia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Inflammation	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Influenza like illness	10 (0.66%)	5 (0.34%)	2 (0.70%)	17 (0.52%)
Injection site bruising	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Injection site eczema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Injection site erythema	10 (0.66%)	12 (0.81%)	2 (0.70%)	24 (0.73%)
Injection site hypersensitivity	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Injection site induration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Injection site oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Injection site pain	22 (1.46%)	17 (1.15%)	0 (0.00%)	39 (1.19%)
Injection site paraesthesia	1 (0.07%)	6 (0.41%)	0 (0.00%)	7 (0.21%)
Injection site pruritus	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)
Injection site rash	9 (0.60%)	7 (0.47%)	0 (0.00%)	16 (0.49%)
Injection site reaction	42 (2.78%)	49 (3.32%)	2 (0.70%)	93 (2.84%)
Injection site vesicles	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Injury associated with device	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Malaise	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Mass	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Mucosal inflammation	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Nodule	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Non-cardiac chest pain	10 (0.66%)	11 (0.74%)	1 (0.35%)	22 (0.67%)
Oedema	3 (0.20%)	3 (0.20%)	3 (1.06%)	9 (0.27%)
Oedema peripheral	29 (1.92%)	20 (1.35%)	2 (0.70%)	51 (1.56%)
Pain	7 (0.46%)	5 (0.34%)	1 (0.35%)	13 (0.40%)

Peripheral swelling	13 (0.86%)	14 (0.95%)	0 (0.00%)	27 (0.82%)
Physical deconditioning	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Polyp	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Pyrexia	8 (0.53%)	13 (0.88%)	0 (0.00%)	21 (0.64%)
Sensation of foreign body	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Swelling face	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Vessel puncture site bruise	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Vessel puncture site haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hepatobiliary disorders				
Alcoholic liver disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Biliary colic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Biliary dilatation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cholecystitis	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Cholecystitis acute	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cholecystitis chronic	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Cholelithiasis	11 (0.73%)	16 (1.08%)	1 (0.35%)	28 (0.86%)
Gallbladder polyp	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Hepatic calcification	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hepatic cirrhosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Hepatic cyst	0 (0.00%)	6 (0.41%)	0 (0.00%)	6 (0.18%)
Hepatic fibrosis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Hepatic function abnormal	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Hepatic haematoma	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Hepatic lesion	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Hepatic steatosis	17 (1.12%)	17 (1.15%)	4 (1.41%)	38 (1.16%)

Hepatomegaly	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Hyperbilirubinaemia	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Hypertransaminasaemia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Liver injury	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Non-alcoholic fatty liver	1 (0.07%)	2 (0.14%)	1 (0.35%)	4 (0.12%)

Immune system disorders

Allergy to arthropod bite	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Allergy to arthropod sting	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Contrast media allergy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Drug hypersensitivity	3 (0.20%)	3 (0.20%)	1 (0.35%)	7 (0.21%)
Dust allergy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Food allergy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hypersensitivity	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Immunisation reaction	5 (0.33%)	7 (0.47%)	1 (0.35%)	13 (0.40%)
Sarcoidosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Seasonal allergy	9 (0.60%)	16 (1.08%)	1 (0.35%)	26 (0.79%)

Infections and infestations

Abdominal abscess	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Abscess	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Abscess limb	3 (0.20%)	2 (0.14%)	0 (0.00%)	5 (0.15%)
Abscess of eyelid	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Acarodermatitis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Acute sinusitis	10 (0.66%)	7 (0.47%)	0 (0.00%)	17 (0.52%)
Appendicitis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Arthritis infective	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Aspergillus infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Asymptomatic bacteriuria	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Asymptomatic COVID-19	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Bacteraemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bacterial infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bacterial vaginosis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Bartholinitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blister infected	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Body tinea	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Borrelia infection	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Breast cellulitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bronchitis	32 (2.12%)	27 (1.83%)	1 (0.35%)	60 (1.83%)
Bronchitis viral	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bronchopulmonary aspergillosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Candida infection	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Cellulitis	20 (1.32%)	20 (1.35%)	3 (1.06%)	43 (1.31%)
Chronic sinusitis	2 (0.13%)	5 (0.34%)	0 (0.00%)	7 (0.21%)
Conjunctivitis	4 (0.26%)	2 (0.14%)	0 (0.00%)	6 (0.18%)
Conjunctivitis bacterial	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Coronavirus infection	5 (0.33%)	5 (0.34%)	4 (1.41%)	14 (0.43%)
COVID-19	178 (11.77%)	176 (11.91%)	52 (18.31%)	406 (12.40%)
COVID-19 pneumonia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cystitis	6 (0.40%)	6 (0.41%)	1 (0.35%)	13 (0.40%)
Dacryocystitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dermatophytosis of nail	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Device related infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Diverticulitis	2 (0.13%)	7 (0.47%)	2 (0.70%)	11 (0.34%)
Ear infection	5 (0.33%)	10 (0.68%)	1 (0.35%)	16 (0.49%)
Eczema infected	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Epididymitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Erysipelas	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Erythema migrans	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Escherichia urinary tract infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
External ear cellulitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eye infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Eye infection viral	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Eyelid infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Folliculitis	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Fungal foot infection	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Fungal infection	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Fungal skin infection	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Furuncle	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Gangrene	1 (0.07%)	1 (0.07%)	1 (0.35%)	3 (0.09%)
Gastroenteritis	14 (0.93%)	13 (0.88%)	0 (0.00%)	27 (0.82%)
Gastroenteritis clostridial	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Gastroenteritis viral	2 (0.13%)	6 (0.41%)	0 (0.00%)	8 (0.24%)
Gastrointestinal viral infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Genital candidiasis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Genital herpes	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Gingivitis	1 (0.07%)	3 (0.20%)	1 (0.35%)	5 (0.15%)
Groin abscess	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Gynaecological chlamydia infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Helicobacter gastritis	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Helicobacter infection	0 (0.00%)	5 (0.34%)	1 (0.35%)	6 (0.18%)
Herpes dermatitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Herpes simplex	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Herpes virus infection	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Herpes zoster	16 (1.06%)	9 (0.61%)	0 (0.00%)	25 (0.76%)
Herpes zoster infection neurological	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hordeolum	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Infected bite	3 (0.20%)	2 (0.14%)	1 (0.35%)	6 (0.18%)
Infected dermal cyst	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Infected skin ulcer	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Infection	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Infective exacerbation of chronic obstructive airways disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Influenza	18 (1.19%)	15 (1.01%)	0 (0.00%)	33 (1.01%)
Injection site cellulitis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Kidney infection	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Klebsiella infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Labyrinthitis	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Laryngitis	5 (0.33%)	2 (0.14%)	1 (0.35%)	8 (0.24%)
Localised infection	3 (0.20%)	10 (0.68%)	0 (0.00%)	13 (0.40%)

Lower respiratory tract infection	29 (1.92%)	19 (1.29%)	7 (2.46%)	55 (1.68%)
Lower respiratory tract infection bacterial	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lyme disease	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Lymphangitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Mastitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Nail bed infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nail infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nasopharyngitis	61 (4.03%)	44 (2.98%)	5 (1.76%)	110 (3.36%)
Onychomycosis	12 (0.79%)	2 (0.14%)	0 (0.00%)	14 (0.43%)
Ophthalmic herpes zoster	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Oral candidiasis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Oral fungal infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Oral herpes	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Oral infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Orchitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Osteomyelitis	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Otitis externa	2 (0.13%)	6 (0.41%)	0 (0.00%)	8 (0.24%)
Otitis media	4 (0.26%)	3 (0.20%)	0 (0.00%)	7 (0.21%)
Otitis media acute	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Otitis media chronic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Paronychia	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Parotitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Penile infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Perineal infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Periodontitis	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Pharyngitis	8 (0.53%)	2 (0.14%)	0 (0.00%)	10 (0.31%)
Pharyngitis streptococcal	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Pneumonia	28 (1.85%)	20 (1.35%)	2 (0.70%)	50 (1.53%)
Post procedural infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Post-acute COVID-19 syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pseudomonas infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pulmonary tuberculosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pulpitis dental	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Pyelonephritis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Pyelonephritis chronic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Rectal abscess	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Respiratory tract infection	7 (0.46%)	9 (0.61%)	0 (0.00%)	16 (0.49%)
Respiratory tract infection viral	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Rhinitis	7 (0.46%)	2 (0.14%)	3 (1.06%)	12 (0.37%)
Root canal infection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Rotavirus infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sepsis	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Septic shock	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sinobronchitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sinusitis	14 (0.93%)	30 (2.03%)	1 (0.35%)	45 (1.37%)
Sinusitis bacterial	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Skin candida	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Skin infection	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)

Staphylococcal bacteraemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Staphylococcal infection	5 (0.33%)	0 (0.00%)	0 (0.00%)	5 (0.15%)
Staphylococcal sepsis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Staphylococcal skin infection	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Subcutaneous abscess	4 (0.26%)	4 (0.27%)	0 (0.00%)	8 (0.24%)
Suspected COVID-19	0 (0.00%)	4 (0.27%)	0 (0.00%)	4 (0.12%)
Tick-borne fever	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Tinea infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Tinea pedis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Tonsillitis	0 (0.00%)	3 (0.20%)	1 (0.35%)	4 (0.12%)
Tooth abscess	8 (0.53%)	12 (0.81%)	1 (0.35%)	21 (0.64%)
Tooth infection	5 (0.33%)	3 (0.20%)	1 (0.35%)	9 (0.27%)
Tracheitis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Tracheobronchitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Upper respiratory tract infection	56 (3.70%)	50 (3.38%)	4 (1.41%)	110 (3.36%)
Urinary tract infection	77 (5.09%)	60 (4.06%)	10 (3.52%)	147 (4.49%)
Vaginal infection	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Varicella zoster virus infection	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Vestibular neuronitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Viral infection	8 (0.53%)	2 (0.14%)	2 (0.70%)	12 (0.37%)
Viral upper respiratory tract infection	0 (0.00%)	3 (0.20%)	1 (0.35%)	4 (0.12%)
Vulvitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vulvovaginal candidiasis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Vulvovaginal mycotic infection	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Wound infection	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Injury, poisoning and procedural complications				
Accident	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Administration related reaction	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Alcohol poisoning	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Anaemia postoperative	3 (0.20%)	2 (0.14%)	0 (0.00%)	5 (0.15%)
Animal bite	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Animal scratch	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ankle fracture	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Arterial injury	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Arthropod bite	5 (0.33%)	8 (0.54%)	1 (0.35%)	14 (0.43%)
Arthropod sting	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Avulsion fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Back injury	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Bone contusion	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Brain contusion	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Burns first degree	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cartilage injury	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Chest injury	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Clavicle fracture	2 (0.13%)	2 (0.14%)	1 (0.35%)	5 (0.15%)
Comminuted fracture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Complications of transplanted lung	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Concussion	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Contusion	15 (0.99%)	21 (1.42%)	2 (0.70%)	38 (1.16%)
Corneal abrasion	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Costochondral separation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ear injury	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Electric shock	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Epicondylitis	2 (0.13%)	1 (0.07%)	1 (0.35%)	4 (0.12%)
Eye contusion	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Eye injury	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Face injury	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Facial bones fracture	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Fall	33 (2.18%)	42 (2.84%)	6 (2.11%)	81 (2.47%)
Femur fracture	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Fibula fracture	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Foot fracture	3 (0.20%)	4 (0.27%)	1 (0.35%)	8 (0.24%)
Forearm fracture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Foreign body	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Foreign body in ear	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Foreign body in eye	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Fractured sacrum	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Hand fracture	8 (0.53%)	3 (0.20%)	1 (0.35%)	12 (0.37%)
Head injury	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Heat exhaustion	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Humerus fracture	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Incisional hernia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Injection related reaction	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)

Injury	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Intra-ocular injection complication	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Jaw fracture	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Joint dislocation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Joint injury	4 (0.26%)	7 (0.47%)	1 (0.35%)	12 (0.37%)
Ligament rupture	0 (0.00%)	2 (0.14%)	1 (0.35%)	3 (0.09%)
Ligament sprain	8 (0.53%)	7 (0.47%)	0 (0.00%)	15 (0.46%)
Limb crushing injury	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Limb fracture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Limb injury	10 (0.66%)	15 (1.01%)	1 (0.35%)	26 (0.79%)
Limb traumatic amputation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Lower limb fracture	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Lumbar vertebral fracture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Meniscus injury	5 (0.33%)	2 (0.14%)	0 (0.00%)	7 (0.21%)
Multiple injuries	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Muscle injury	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Muscle rupture	1 (0.07%)	1 (0.07%)	1 (0.35%)	3 (0.09%)
Muscle strain	7 (0.46%)	4 (0.27%)	0 (0.00%)	11 (0.34%)
Musculoskeletal foreign body	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Neck injury	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Patella fracture	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Pelvic fracture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Peripancreatic fluid collection	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Post procedural complication	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Post procedural constipation	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Post procedural haemorrhage	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Post procedural hypothyroidism	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Post procedural inflammation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Post vaccination syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Postoperative thoracic procedure complication	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Postoperative wound complication	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Post-traumatic pain	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Procedural complication	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Procedural headache	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Procedural nausea	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Procedural pain	4 (0.26%)	10 (0.68%)	3 (1.06%)	17 (0.52%)
Radiation injury	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Radiation proctitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Radius fracture	0 (0.00%)	4 (0.27%)	0 (0.00%)	4 (0.12%)
Rib fracture	8 (0.53%)	8 (0.54%)	1 (0.35%)	17 (0.52%)
Road traffic accident	2 (0.13%)	2 (0.14%)	1 (0.35%)	5 (0.15%)
Skin abrasion	7 (0.46%)	5 (0.34%)	0 (0.00%)	12 (0.37%)
Skin injury	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Skin laceration	18 (1.19%)	11 (0.74%)	2 (0.70%)	31 (0.95%)

Skull fracture	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Soft tissue injury	6 (0.40%)	3 (0.20%)	0 (0.00%)	9 (0.27%)
Spinal compression fracture	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Spinal fracture	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Splinter	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Subdural haematoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Synovial rupture	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Tendon injury	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Tendon rupture	2 (0.13%)	2 (0.14%)	1 (0.35%)	5 (0.15%)
Thermal burn	4 (0.26%)	0 (0.00%)	1 (0.35%)	5 (0.15%)
Thoracic vertebral fracture	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Tibia fracture	2 (0.13%)	0 (0.00%)	1 (0.35%)	3 (0.09%)
Tobacco poisoning	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Tooth fracture	2 (0.13%)	3 (0.20%)	1 (0.35%)	6 (0.18%)
Traumatic arthrosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ulna fracture	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Upper limb fracture	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Vaccination complication	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Wound	5 (0.33%)	2 (0.14%)	0 (0.00%)	7 (0.21%)
Wound dehiscence	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Wound haemorrhage	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Wound necrosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Wrist fracture	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)

Investigations

Alanine aminotransferase increased	6 (0.40%)	4 (0.27%)	1 (0.35%)	11 (0.34%)
Antiphospholipid antibodies	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Aortic bruit	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Arteriogram coronary normal	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Aspartate aminotransferase increased	3 (0.20%)	5 (0.34%)	1 (0.35%)	9 (0.27%)
Bilirubin conjugated increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Blood alkaline phosphatase increased	7 (0.46%)	5 (0.34%)	0 (0.00%)	12 (0.37%)
Blood bilirubin increased	6 (0.40%)	7 (0.47%)	1 (0.35%)	14 (0.43%)
Blood bilirubin unconjugated increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood calcium decreased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Blood calcium increased	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Blood cholesterol increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood creatine abnormal	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood creatine phosphokinase increased	27 (1.79%)	31 (2.10%)	0 (0.00%)	58 (1.77%)
Blood creatinine increased	8 (0.53%)	7 (0.47%)	0 (0.00%)	15 (0.46%)
Blood folate decreased	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)
Blood glucose abnormal	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Blood glucose increased	1 (0.07%)	1 (0.07%)	3 (1.06%)	5 (0.15%)
Blood homocysteine increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood iron decreased	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Blood lactate dehydrogenase increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Blood lactic acid increased	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Blood potassium decreased	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Blood potassium increased	2 (0.13%)	1 (0.07%)	1 (0.35%)	4 (0.12%)
Blood pressure ambulatory increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood pressure decreased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood pressure diastolic decreased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Blood pressure increased	13 (0.86%)	14 (0.95%)	0 (0.00%)	27 (0.82%)
Blood pressure systolic increased	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Blood sodium decreased	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Blood sodium increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood testosterone decreased	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Blood thyroid stimulating hormone decreased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood thyroid stimulating hormone increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Blood triglycerides increased	4 (0.26%)	8 (0.54%)	1 (0.35%)	13 (0.40%)
Blood urea increased	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Blood urine present	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Body temperature abnormal	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Borrelia test positive	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Brain natriuretic peptide increased	3 (0.20%)	2 (0.14%)	0 (0.00%)	5 (0.15%)
Carbohydrate antigen 15-3 increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cardiac murmur	5 (0.33%)	5 (0.34%)	0 (0.00%)	10 (0.31%)
Cardiac stress test abnormal	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Carotid bruit	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Coronavirus test positive	1 (0.07%)	4 (0.27%)	3 (1.06%)	8 (0.24%)
C-reactive protein increased	8 (0.53%)	7 (0.47%)	2 (0.70%)	17 (0.52%)
Ejection fraction decreased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Electrocardiogram abnormal	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Electrocardiogram QT prolonged	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Electrocardiogram repolarisation abnormality	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Electrocardiogram ST-T change	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Electrocardiogram T wave inversion	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Fibrin D dimer increased	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Gamma-glutamyltransferase abnormal	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Gamma-glutamyltransferase increased	16 (1.06%)	23 (1.56%)	0 (0.00%)	39 (1.19%)
Glomerular filtration rate decreased	9 (0.60%)	8 (0.54%)	1 (0.35%)	18 (0.55%)

Glucose urine present	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Glycosylated haemoglobin increased	13 (0.86%)	15 (1.01%)	1 (0.35%)	29 (0.89%)
Haematology test abnormal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Haemoglobin decreased	3 (0.20%)	2 (0.14%)	1 (0.35%)	6 (0.18%)
Haemoglobin increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Heart rate decreased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Heart rate irregular	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Helicobacter test positive	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hepatic enzyme abnormal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hepatic enzyme increased	9 (0.60%)	7 (0.47%)	1 (0.35%)	17 (0.52%)
Immunoglobulins decreased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Immunoglobulins increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
International normalised ratio increased	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Intraocular pressure increased	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Laboratory test abnormal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Lipase increased	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Lipids increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Lipoprotein (a) increased	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Lipoprotein increased	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Liver function test abnormal	0 (0.00%)	6 (0.41%)	1 (0.35%)	7 (0.21%)
Liver function test increased	2 (0.13%)	7 (0.47%)	0 (0.00%)	9 (0.27%)

Low density lipoprotein increased	5 (0.33%)	3 (0.20%)	0 (0.00%)	8 (0.24%)
Mean cell volume increased	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Monofilament pressure perception test abnormal	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Nitrite urine	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
N-terminal prohormone brain natriuretic peptide increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Occult blood positive	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Oxygen saturation decreased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Platelet count decreased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Prostatic specific antigen increased	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Protein urine present	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Respiratory rate increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Romberg test positive	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
SARS-CoV-2 test positive	1 (0.07%)	2 (0.14%)	1 (0.35%)	4 (0.12%)
Scan myocardial perfusion abnormal	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Serum ferritin decreased	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Serum ferritin increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Thyroxine increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Transaminases increased	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Troponin increased	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Tryptase increased	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Ultrasound Doppler abnormal	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Ultrasound scan abnormal	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Urinary system x-ray abnormal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Urine analysis abnormal	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Urine output decreased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Vitamin D decreased	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Weight decreased	12 (0.79%)	7 (0.47%)	0 (0.00%)	19 (0.58%)
Weight increased	4 (0.26%)	2 (0.14%)	0 (0.00%)	6 (0.18%)
White blood cell count increased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
White blood cells urine positive	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Metabolism and nutrition disorders				
Abnormal loss of weight	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Acidosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cachexia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Carbohydrate intolerance	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Decreased appetite	4 (0.26%)	4 (0.27%)	0 (0.00%)	8 (0.24%)
Dehydration	10 (0.66%)	11 (0.74%)	0 (0.00%)	21 (0.64%)
Diabetes mellitus	98 (6.48%)	100 (6.77%)	7 (2.46%)	205 (6.26%)
Diabetes mellitus inadequate control	114 (7.54%)	109 (7.37%)	3 (1.06%)	226 (6.90%)
Diabetic complication	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Diabetic ketoacidosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Diabetic metabolic decompensation	4 (0.26%)	4 (0.27%)	0 (0.00%)	8 (0.24%)
Electrolyte imbalance	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Fluid retention	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Folate deficiency	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Fructose intolerance	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Glucose tolerance impaired	15 (0.99%)	10 (0.68%)	0 (0.00%)	25 (0.76%)
Gout	15 (0.99%)	21 (1.42%)	1 (0.35%)	37 (1.13%)
Hypercalcaemia	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Hypercholesterolaemia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Hyperglycaemia	6 (0.40%)	9 (0.61%)	1 (0.35%)	16 (0.49%)
Hyperhomocysteinaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hyperkalaemia	8 (0.53%)	8 (0.54%)	1 (0.35%)	17 (0.52%)
Hyperlipidaemia	7 (0.46%)	4 (0.27%)	1 (0.35%)	12 (0.37%)
Hypermagnesaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hypernatraemia	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Hyperphosphataemia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Hypertriglyceridaemia	10 (0.66%)	6 (0.41%)	0 (0.00%)	16 (0.49%)
Hyperuricaemia	9 (0.60%)	7 (0.47%)	0 (0.00%)	16 (0.49%)
Hypervitaminosis D	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hypervolaemia	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Hypoalbuminaemia	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Hypocalcaemia	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Hypoglycaemia	5 (0.33%)	4 (0.27%)	1 (0.35%)	10 (0.31%)
Hypokalaemia	19 (1.26%)	13 (0.88%)	0 (0.00%)	32 (0.98%)
Hypomagnesaemia	8 (0.53%)	2 (0.14%)	0 (0.00%)	10 (0.31%)

Hyponatraemia	5 (0.33%)	5 (0.34%)	1 (0.35%)	11 (0.34%)
Hypophosphataemia	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Hypovolaemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Impaired fasting glucose	4 (0.26%)	2 (0.14%)	0 (0.00%)	6 (0.18%)
Insulin resistance	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Iron deficiency	5 (0.33%)	2 (0.14%)	0 (0.00%)	7 (0.21%)
Lactic acidosis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Latent autoimmune diabetes in adults	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Magnesium deficiency	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Malnutrition	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Metabolic acidosis	1 (0.07%)	5 (0.34%)	0 (0.00%)	6 (0.18%)
Metabolic disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Obesity	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Overweight	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Postprandial hypoglycaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Type 2 diabetes mellitus	32 (2.12%)	41 (2.77%)	4 (1.41%)	77 (2.35%)
Vitamin B complex deficiency	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vitamin B12 deficiency	6 (0.40%)	3 (0.20%)	0 (0.00%)	9 (0.27%)
Vitamin D deficiency	14 (0.93%)	15 (1.01%)	1 (0.35%)	30 (0.92%)
Musculoskeletal and connective tissue disorders				
Ankle impingement	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Arthralgia	94 (6.22%)	102 (6.90%)	5 (1.76%)	201 (6.14%)
Arthritis	14 (0.93%)	12 (0.81%)	2 (0.70%)	28 (0.86%)

Arthropathy	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Back pain	67 (4.43%)	51 (3.45%)	8 (2.82%)	126 (3.85%)
Bone atrophy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bone cyst	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bursitis	4 (0.26%)	6 (0.41%)	3 (1.06%)	13 (0.40%)
Cervical spinal stenosis	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Chondrocalcinosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Chondropathy	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Chronic kidney disease-mineral and bone disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Coccydynia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Costochondritis	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Degenerative bone disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Diffuse idiopathic skeletal hyperostosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Dupuytren's contracture	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Exostosis	3 (0.20%)	1 (0.07%)	1 (0.35%)	5 (0.15%)
Fibromyalgia	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Flank pain	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Foot deformity	4 (0.26%)	4 (0.27%)	1 (0.35%)	9 (0.27%)
Fracture pain	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Greater trochanteric pain syndrome	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Groin pain	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Haemarthrosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Haematoma muscle	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Intervertebral disc degeneration	6 (0.40%)	5 (0.34%)	0 (0.00%)	11 (0.34%)
Intervertebral disc disorder	5 (0.33%)	4 (0.27%)	1 (0.35%)	10 (0.31%)
Intervertebral disc protrusion	7 (0.46%)	9 (0.61%)	1 (0.35%)	17 (0.52%)
Joint effusion	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Joint instability	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Joint stiffness	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Joint swelling	6 (0.40%)	5 (0.34%)	1 (0.35%)	12 (0.37%)
Ligament calcification	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Limb discomfort	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Lumbar spinal stenosis	4 (0.26%)	3 (0.20%)	1 (0.35%)	8 (0.24%)
Meniscal degeneration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Mobility decreased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Muscle atrophy	0 (0.00%)	4 (0.27%)	0 (0.00%)	4 (0.12%)
Muscle contracture	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Muscle discomfort	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Muscle fatigue	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Muscle oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Muscle rigidity	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Muscle spasms	26 (1.72%)	10 (0.68%)	1 (0.35%)	37 (1.13%)
Muscle tightness	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Muscular weakness	8 (0.53%)	4 (0.27%)	1 (0.35%)	13 (0.40%)
Musculoskeletal chest pain	4 (0.26%)	3 (0.20%)	1 (0.35%)	8 (0.24%)
Musculoskeletal discomfort	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Musculoskeletal disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Musculoskeletal pain	3 (0.20%)	3 (0.20%)	1 (0.35%)	7 (0.21%)
Myalgia	19 (1.26%)	26 (1.76%)	3 (1.06%)	48 (1.47%)
Myopathy	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Neck mass	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Neck pain	16 (1.06%)	14 (0.95%)	1 (0.35%)	31 (0.95%)
Osteoarthritis	60 (3.97%)	53 (3.59%)	6 (2.11%)	119 (3.63%)
Osteochondrosis	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Osteonecrosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Osteopenia	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)
Osteoporosis	3 (0.20%)	8 (0.54%)	2 (0.70%)	13 (0.40%)
Osteoporosis postmenopausal	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pain in extremity	43 (2.84%)	38 (2.57%)	5 (1.76%)	86 (2.63%)
Pain in jaw	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Patellofemoral pain syndrome	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Periarthritis	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Periostitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Plantar fasciitis	9 (0.60%)	4 (0.27%)	1 (0.35%)	14 (0.43%)
Polymyalgia rheumatica	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Psoriatic arthropathy	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Rheumatoid arthritis	5 (0.33%)	4 (0.27%)	0 (0.00%)	9 (0.27%)
Rib deformity	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Rotator cuff syndrome	14 (0.93%)	14 (0.95%)	2 (0.70%)	30 (0.92%)
Sacral pain	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Sacroiliac joint dysfunction	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)

Sacroiliitis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Scoliosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
SLE arthritis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Soft tissue swelling	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Spinal osteoarthritis	12 (0.79%)	15 (1.01%)	2 (0.70%)	29 (0.89%)
Spinal pain	4 (0.26%)	7 (0.47%)	0 (0.00%)	11 (0.34%)
Spinal stenosis	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Spondylitis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Spondylolisthesis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Synovial cyst	7 (0.46%)	5 (0.34%)	0 (0.00%)	12 (0.37%)
Systemic lupus erythematosus	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Temporomandibular joint syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Tendon disorder	0 (0.00%)	4 (0.27%)	0 (0.00%)	4 (0.12%)
Tendonitis	3 (0.20%)	4 (0.27%)	2 (0.70%)	9 (0.27%)
Tenosynovitis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Tenosynovitis stenosans	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Torticollis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Trigger finger	10 (0.66%)	7 (0.47%)	1 (0.35%)	18 (0.55%)
Trismus	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)				
Acrochordon	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Adrenal adenoma	1 (0.07%)	2 (0.14%)	1 (0.35%)	4 (0.12%)
Adrenal neoplasm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Basal cell carcinoma	24 (1.59%)	5 (0.34%)	1 (0.35%)	30 (0.92%)
B-cell lymphoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Benign bone neoplasm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Benign laryngeal neoplasm	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Benign neoplasm of bladder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Benign neoplasm of skin	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Benign neoplasm of thyroid gland	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Bladder cancer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bladder papilloma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bowen's disease	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Breast cancer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Breast cancer metastatic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cholesteatoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Chronic myeloid leukaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Colorectal adenoma	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Dysplastic naevus	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Eye naevus	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Fibroma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Fibrous histiocytoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gastrointestinal tract adenoma	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Haemangioma	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Haemangioma of liver	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Haemangioma of skin	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Hypergammaglobulinaemia benign monoclonal	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Juvenile melanoma benign	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Leiomyoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Lipoma	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Lymphoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Mantle cell lymphoma	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Melanocytic naevus	5 (0.33%)	2 (0.14%)	0 (0.00%)	7 (0.21%)
Meningioma	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Metastases to bone	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Metastases to liver	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Metastatic malignant melanoma	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Metastatic neoplasm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Myelodysplastic syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Oesophageal papilloma	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Oral papilloma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pancreatic neoplasm	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Parathyroid tumour benign	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Phaeochromocytoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pituitary tumour	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pituitary tumour benign	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Plasma cell myeloma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Prostate cancer	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Prostatic adenoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Renal cancer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Renal cell carcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Renal hamartoma	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Seborrhoeic keratosis	5 (0.33%)	4 (0.27%)	3 (1.06%)	12 (0.37%)
Skin cancer	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Skin papilloma	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Skin squamous cell carcinoma recurrent	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Squamous cell carcinoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Squamous cell carcinoma of skin	0 (0.00%)	3 (0.20%)	1 (0.35%)	4 (0.12%)
Thyroid adenoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Thyroid cancer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Tumour pain	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Uterine leiomyoma	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Vulvovaginal warts	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nervous system disorders				
Ageusia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Akinesia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Altered state of consciousness	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Amnesia	6 (0.40%)	3 (0.20%)	0 (0.00%)	9 (0.27%)
Aphasia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Arachnoid cyst	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Balance disorder	8 (0.53%)	2 (0.14%)	1 (0.35%)	11 (0.34%)
Bell's palsy	2 (0.13%)	1 (0.07%)	1 (0.35%)	4 (0.12%)
Burning sensation	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)

Carotid arteriosclerosis	3 (0.20%)	2 (0.14%)	1 (0.35%)	6 (0.18%)
Carotid artery disease	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Carotid artery occlusion	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Carotid artery stenosis	6 (0.40%)	4 (0.27%)	0 (0.00%)	10 (0.31%)
Carpal tunnel syndrome	13 (0.86%)	8 (0.54%)	1 (0.35%)	22 (0.67%)
Cerebellar atrophy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cerebral arteriosclerosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cerebral atrophy	2 (0.13%)	1 (0.07%)	1 (0.35%)	4 (0.12%)
Cerebral ischaemia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cerebral microangiopathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cerebral small vessel ischaemic disease	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Cerebrovascular accident	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cerebrovascular disorder	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Cervical radiculopathy	6 (0.40%)	2 (0.14%)	0 (0.00%)	8 (0.24%)
Cervicobrachial syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cervicogenic headache	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cognitive disorder	4 (0.26%)	2 (0.14%)	0 (0.00%)	6 (0.18%)
Cortical laminar necrosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Cubital tunnel syndrome	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dementia	3 (0.20%)	2 (0.14%)	0 (0.00%)	5 (0.15%)
Dementia Alzheimer's type	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Diabetic neuropathy	6 (0.40%)	4 (0.27%)	1 (0.35%)	11 (0.34%)
Disturbance in attention	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dizziness	40 (2.65%)	42 (2.84%)	6 (2.11%)	88 (2.69%)
Dysarthria	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Dysgeusia	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Encephalopathy	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Epilepsy	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Essential tremor	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Facial paralysis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Facial paresis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Head discomfort	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Headache	41 (2.71%)	37 (2.50%)	5 (1.76%)	83 (2.54%)
Hemiparesis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hepatic encephalopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hyperaesthesia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hypoaesthesia	5 (0.33%)	7 (0.47%)	0 (0.00%)	12 (0.37%)
Hyporeflexia	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Hyposmia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Intercostal neuralgia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Intracranial aneurysm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Intracranial mass	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ischaemic stroke	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Lethargy	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Loss of consciousness	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Lumbar radiculopathy	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Lumbosacral radiculopathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Memory impairment	5 (0.33%)	2 (0.14%)	1 (0.35%)	8 (0.24%)
Migraine	5 (0.33%)	1 (0.07%)	0 (0.00%)	6 (0.18%)
Morton's neuralgia	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)

Muscle contractions involuntary	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Myelopathy	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Nerve compression	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Neuralgia	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Neuropathy peripheral	18 (1.19%)	11 (0.74%)	4 (1.41%)	33 (1.01%)
Pachymeningitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Paraesthesia	6 (0.40%)	4 (0.27%)	2 (0.70%)	12 (0.37%)
Paralysis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Parkinson's disease	5 (0.33%)	3 (0.20%)	0 (0.00%)	8 (0.24%)
Partial seizures	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Periodic limb movement disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Peripheral sensorimotor neuropathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Peroneal nerve palsy	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Polyneuropathy	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Post herpetic neuralgia	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Post polio syndrome	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Presyncope	6 (0.40%)	4 (0.27%)	1 (0.35%)	11 (0.34%)
Quadrantanopia	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Radiculopathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Restless legs syndrome	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Sciatica	15 (0.99%)	22 (1.49%)	1 (0.35%)	38 (1.16%)
Seizure	4 (0.26%)	2 (0.14%)	0 (0.00%)	6 (0.18%)
Senile dementia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sensory disturbance	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Sensory loss	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Somnolence	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Speech disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Spinal claudication	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Syncope	16 (1.06%)	15 (1.01%)	0 (0.00%)	31 (0.95%)
Taste disorder	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Tension headache	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Thoracic radiculopathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Thunderclap headache	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Transient global amnesia	1 (0.07%)	0 (0.00%)	1 (0.35%)	2 (0.06%)
Transient ischaemic attack	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Tremor	7 (0.46%)	4 (0.27%)	1 (0.35%)	12 (0.37%)
Trigeminal neuralgia	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Ulnar neuritis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Vascular dementia	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Vascular encephalopathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vascular parkinsonism	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vertebrobasilar insufficiency	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vlth nerve paralysis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vocal cord paralysis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Product issues				
Device dislocation	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Device malfunction	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Device physical property issue	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Psychiatric disorders

Abnormal behaviour	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Abnormal dreams	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Acute stress disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Adjustment disorder with depressed mood	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Agitation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Alcohol abuse	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Alcoholism	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Anxiety	16 (1.06%)	21 (1.42%)	1 (0.35%)	38 (1.16%)
Anxiety disorder	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Attention deficit hyperactivity disorder	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Bipolar disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bipolar II disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Confusional state	6 (0.40%)	1 (0.07%)	0 (0.00%)	7 (0.21%)
Delirium	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Delusion	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Depressed mood	5 (0.33%)	4 (0.27%)	0 (0.00%)	9 (0.27%)
Depression	29 (1.92%)	19 (1.29%)	3 (1.06%)	51 (1.56%)
Grief reaction	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Habit cough	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hallucination	4 (0.26%)	0 (0.00%)	0 (0.00%)	4 (0.12%)
Hallucination, visual	0 (0.00%)	3 (0.20%)	0 (0.00%)	3 (0.09%)
Initial insomnia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Insomnia	13 (0.86%)	15 (1.01%)	0 (0.00%)	28 (0.86%)

Irritability	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Libido decreased	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Loss of libido	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Mental status changes	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Nightmare	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Obsessive-compulsive disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Panic attack	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Poor quality sleep	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Post-traumatic stress disorder	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Restlessness	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Schizoaffective disorder bipolar type	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Sleep disorder	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Stress	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Suicidal ideation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Renal and urinary disorders				
Acute kidney injury	11 (0.73%)	18 (1.22%)	0 (0.00%)	29 (0.89%)
Albuminuria	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Azotaemia	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bladder disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bladder diverticulum	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Bladder irritation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bladder outlet obstruction	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Bladder prolapse	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Bladder stenosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Chronic kidney disease	23 (1.52%)	20 (1.35%)	1 (0.35%)	44 (1.34%)
Cystitis haemorrhagic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Cystitis noninfective	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Diabetic nephropathy	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Dysuria	6 (0.40%)	2 (0.14%)	2 (0.70%)	10 (0.31%)
End stage renal disease	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Genitourinary symptom	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Glycosuria	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Haematuria	14 (0.93%)	13 (0.88%)	0 (0.00%)	27 (0.82%)
Hydronephrosis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Hypertensive nephropathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hypertonic bladder	5 (0.33%)	6 (0.41%)	0 (0.00%)	11 (0.34%)
Leukocyturia	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Lower urinary tract symptoms	1 (0.07%)	3 (0.20%)	0 (0.00%)	4 (0.12%)
Microalbuminuria	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Micturition urgency	1 (0.07%)	1 (0.07%)	1 (0.35%)	3 (0.09%)
Nephritic syndrome	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nephrolithiasis	15 (0.99%)	10 (0.68%)	1 (0.35%)	26 (0.79%)
Nephropathy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Neurogenic bladder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nocturia	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Pollakiuria	6 (0.40%)	4 (0.27%)	0 (0.00%)	10 (0.31%)
Polyuria	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Proteinuria	4 (0.26%)	2 (0.14%)	0 (0.00%)	6 (0.18%)

Pyelocaliectasis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Renal aneurysm	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Renal artery stenosis	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Renal colic	4 (0.26%)	2 (0.14%)	0 (0.00%)	6 (0.18%)
Renal cyst	9 (0.60%)	22 (1.49%)	0 (0.00%)	31 (0.95%)
Renal disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Renal failure	5 (0.33%)	6 (0.41%)	0 (0.00%)	11 (0.34%)
Renal impairment	24 (1.59%)	30 (2.03%)	0 (0.00%)	54 (1.65%)
Renal mass	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Renal necrosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Renal pain	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Strangury	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Stress urinary incontinence	4 (0.26%)	0 (0.00%)	0 (0.00%)	4 (0.12%)
Tubulointerstitial nephritis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ureterolithiasis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Urethral stenosis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Urge incontinence	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Urinary bladder haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Urinary incontinence	6 (0.40%)	5 (0.34%)	1 (0.35%)	12 (0.37%)
Urinary retention	5 (0.33%)	4 (0.27%)	0 (0.00%)	9 (0.27%)
Urinary tract disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Urinary tract inflammation	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Urine odour abnormal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

**Reproductive system and
breast disorders**

Acquired phimosis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Atrophic vulvovaginitis	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Benign prostatic hyperplasia	26 (1.72%)	20 (1.35%)	2 (0.70%)	48 (1.47%)
Breast disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Breast mass	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Breast necrosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Endometrial hyperplasia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Erectile dysfunction	11 (0.73%)	8 (0.54%)	2 (0.70%)	21 (0.64%)
Genital prolapse	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Gynaecomastia	0 (0.00%)	3 (0.20%)	1 (0.35%)	4 (0.12%)
Heavy menstrual bleeding	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Menopausal symptoms	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nipple exudate bloody	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Ovarian calcification	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ovarian mass	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pelvic pain	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Penile discharge	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Peyronie's disease	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Postmenopausal haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Prostatic mass	0 (0.00%)	1 (0.07%)	1 (0.35%)	2 (0.06%)
Prostatism	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Prostatitis	2 (0.13%)	6 (0.41%)	1 (0.35%)	9 (0.27%)
Prostatomegaly	6 (0.40%)	5 (0.34%)	0 (0.00%)	11 (0.34%)
Rectocele	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)

Scrotal oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Scrotal pain	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Sexual dysfunction	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Spermatocele	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Testicular hypertrophy	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Testicular mass	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Testicular pain	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Uterine prolapse	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vaginal discharge	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vaginal haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vaginal prolapse	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Vulva cyst	2 (0.13%)	0 (0.00%)	1 (0.35%)	3 (0.09%)
Vulvovaginal dryness	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vulvovaginal inflammation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Vulvovaginal pruritus	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Respiratory, thoracic and mediastinal disorders				
Acquired diaphragmatic eventration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Acute pulmonary oedema	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Acute respiratory failure	1 (0.07%)	4 (0.27%)	1 (0.35%)	6 (0.18%)
Allergic sinusitis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Aspiration	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Asthma	10 (0.66%)	5 (0.34%)	2 (0.70%)	17 (0.52%)
Asthma exercise induced	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Atelectasis	1 (0.07%)	4 (0.27%)	0 (0.00%)	5 (0.15%)

Bronchial hyperreactivity	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Bronchial secretion retention	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Bronchiectasis	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Bronchospasm	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Chronic obstructive pulmonary disease	13 (0.86%)	24 (1.62%)	2 (0.70%)	39 (1.19%)
Cough	36 (2.38%)	32 (2.17%)	3 (1.06%)	71 (2.17%)
Diaphragmatic disorder	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Dry throat	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Dysphonia	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Dyspnoea	39 (2.58%)	31 (2.10%)	6 (2.11%)	76 (2.32%)
Dyspnoea exertional	11 (0.73%)	9 (0.61%)	3 (1.06%)	23 (0.70%)
Emphysema	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Epiglottic oedema	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Epistaxis	10 (0.66%)	6 (0.41%)	0 (0.00%)	16 (0.49%)
Haemoptysis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Hiccups	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Hypoxia	4 (0.26%)	0 (0.00%)	0 (0.00%)	4 (0.12%)
Idiopathic pulmonary fibrosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Interstitial lung disease	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Laryngeal ulceration	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lung infiltration	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Lung opacity	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nasal congestion	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Nasal mucosal blistering	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Nasal polyps	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Nasal septum deviation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Obstructive airways disorder	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Obstructive sleep apnoea syndrome	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Oropharyngeal pain	6 (0.40%)	6 (0.41%)	1 (0.35%)	13 (0.40%)
Paranasal cyst	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Paranasal sinus discomfort	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Paranasal sinus inflammation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pleural effusion	5 (0.33%)	12 (0.81%)	1 (0.35%)	18 (0.55%)
Pleural thickening	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Pleurisy	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Pleuritic pain	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pneumothorax	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Productive cough	3 (0.20%)	4 (0.27%)	0 (0.00%)	7 (0.21%)
Pulmonary calcification	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pulmonary congestion	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Pulmonary embolism	5 (0.33%)	1 (0.07%)	0 (0.00%)	6 (0.18%)
Pulmonary fibrosis	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Pulmonary hypertension	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Pulmonary mass	7 (0.46%)	6 (0.41%)	0 (0.00%)	13 (0.40%)
Pulmonary oedema	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Rales	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Reflux laryngitis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Respiratory acidosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Respiratory disorder	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Respiratory failure	3 (0.20%)	1 (0.07%)	0 (0.00%)	4 (0.12%)
Rhinitis allergic	5 (0.33%)	6 (0.41%)	0 (0.00%)	11 (0.34%)
Rhinorrhoea	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Sinus congestion	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Sinus disorder	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sinus polyp	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sleep apnoea syndrome	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Sneezing	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Throat irritation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Throat tightness	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Upper respiratory tract congestion	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Upper-airway cough syndrome	3 (0.20%)	4 (0.27%)	1 (0.35%)	8 (0.24%)
Vocal cord cyst	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Wheezing	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Skin and subcutaneous tissue disorders				
Acne	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Actinic keratosis	5 (0.33%)	4 (0.27%)	2 (0.70%)	11 (0.34%)
Alopecia	1 (0.07%)	3 (0.20%)	1 (0.35%)	5 (0.15%)
Alopecia areata	2 (0.13%)	1 (0.07%)	0 (0.00%)	3 (0.09%)
Angioedema	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Blister	4 (0.26%)	3 (0.20%)	0 (0.00%)	7 (0.21%)
Cutaneous calcification	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Decubitus ulcer	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)

Dermal cyst	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Dermatitis	2 (0.13%)	3 (0.20%)	1 (0.35%)	6 (0.18%)
Dermatitis acneiform	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Dermatitis allergic	3 (0.20%)	3 (0.20%)	0 (0.00%)	6 (0.18%)
Dermatitis contact	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Dermatitis diaper	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Diabetic foot	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Diabetic ulcer	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Dry skin	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Dyshidrotic eczema	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ecchymosis	2 (0.13%)	0 (0.00%)	0 (0.00%)	2 (0.06%)
Eczema	6 (0.40%)	7 (0.47%)	1 (0.35%)	14 (0.43%)
Eczema asteatotic	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Erythema	3 (0.20%)	2 (0.14%)	5 (1.76%)	10 (0.31%)
Hand dermatitis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Hidradenitis	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Hyperhidrosis	5 (0.33%)	3 (0.20%)	0 (0.00%)	8 (0.24%)
Hyperkeratosis	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Hypertrophic scar	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Ingrowing nail	3 (0.20%)	0 (0.00%)	0 (0.00%)	3 (0.09%)
Intertrigo	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lentigo	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lichen planus	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Lipohypertrophy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Milia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Nail dystrophy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)

Night sweats	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Panniculitis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Pemphigus	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pityriasis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pityriasis rosea	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Polymorphic light eruption	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Pruritus	8 (0.53%)	7 (0.47%)	1 (0.35%)	16 (0.49%)
Pruritus allergic	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Psoriasis	6 (0.40%)	2 (0.14%)	0 (0.00%)	8 (0.24%)
Purpura senile	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Rash	13 (0.86%)	9 (0.61%)	1 (0.35%)	23 (0.70%)
Rash erythematous	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Rash pruritic	2 (0.13%)	0 (0.00%)	1 (0.35%)	3 (0.09%)
Reactive perforating collagenosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Rosacea	3 (0.20%)	1 (0.07%)	1 (0.35%)	5 (0.15%)
Sebaceous hyperplasia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Sensitive skin	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Skin discolouration	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Skin fibrosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Skin indentation	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Skin lesion	6 (0.40%)	7 (0.47%)	1 (0.35%)	14 (0.43%)
Skin reaction	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Skin texture abnormal	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Skin ulcer	6 (0.40%)	6 (0.41%)	1 (0.35%)	13 (0.40%)
Stasis dermatitis	2 (0.13%)	0 (0.00%)	2 (0.70%)	4 (0.12%)

Subcutaneous emphysema	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Urticaria	4 (0.26%)	1 (0.07%)	0 (0.00%)	5 (0.15%)
Xanthoma	0 (0.00%)	0 (0.00%)	1 (0.35%)	1 (0.03%)
Social circumstances				
Family stress	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Vascular disorders				
Aneurysm	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Angiodysplasia	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Angiopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Aortic aneurysm	2 (0.13%)	4 (0.27%)	0 (0.00%)	6 (0.18%)
Aortic aneurysm rupture	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Aortic arteriosclerosis	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Aortic dilatation	2 (0.13%)	3 (0.20%)	0 (0.00%)	5 (0.15%)
Aortic stenosis	6 (0.40%)	3 (0.20%)	1 (0.35%)	10 (0.31%)
Arterial occlusive disease	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Arterial thrombosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Arteriosclerosis	8 (0.53%)	2 (0.14%)	0 (0.00%)	10 (0.31%)
Arteritis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood pressure fluctuation	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Blood pressure inadequately controlled	2 (0.13%)	2 (0.14%)	0 (0.00%)	4 (0.12%)
Circulatory collapse	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Cyanosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Deep vein thrombosis	5 (0.33%)	2 (0.14%)	0 (0.00%)	7 (0.21%)
Diastolic hypertension	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)

Essential hypertension	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Extravasation blood	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Flushing	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Haematoma	3 (0.20%)	3 (0.20%)	1 (0.35%)	7 (0.21%)
Haemorrhage	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Hot flush	0 (0.00%)	4 (0.27%)	0 (0.00%)	4 (0.12%)
Hypertension	106 (7.01%)	110 (7.44%)	9 (3.17%)	225 (6.87%)
Hypertensive crisis	3 (0.20%)	2 (0.14%)	0 (0.00%)	5 (0.15%)
Hypertensive urgency	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Hypotension	21 (1.39%)	21 (1.42%)	1 (0.35%)	43 (1.31%)
Iliac artery arteriosclerosis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Iliac artery stenosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Intermittent claudication	0 (0.00%)	5 (0.34%)	3 (1.06%)	8 (0.24%)
Jugular vein thrombosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Lymphoedema	3 (0.20%)	0 (0.00%)	1 (0.35%)	4 (0.12%)
Microangiopathy	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Orthostatic hypertension	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Orthostatic hypotension	3 (0.20%)	5 (0.34%)	0 (0.00%)	8 (0.24%)
Peripheral arterial occlusive disease	11 (0.73%)	10 (0.68%)	1 (0.35%)	22 (0.67%)
Peripheral artery occlusion	2 (0.13%)	5 (0.34%)	0 (0.00%)	7 (0.21%)
Peripheral artery stenosis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Peripheral coldness	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Peripheral ischaemia	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Peripheral vascular disorder	5 (0.33%)	2 (0.14%)	0 (0.00%)	7 (0.21%)

Peripheral venous disease	6 (0.40%)	8 (0.54%)	0 (0.00%)	14 (0.43%)
Phlebitis	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Phlebitis deep	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Phlebitis superficial	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Post thrombotic syndrome	1 (0.07%)	1 (0.07%)	0 (0.00%)	2 (0.06%)
Raynaud's phenomenon	1 (0.07%)	2 (0.14%)	0 (0.00%)	3 (0.09%)
Superficial vein prominence	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Superficial vein thrombosis	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)
Systolic hypertension	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Thrombophlebitis	3 (0.20%)	2 (0.14%)	0 (0.00%)	5 (0.15%)
Thrombosed varicose vein	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Thrombosis	1 (0.07%)	0 (0.00%)	0 (0.00%)	1 (0.03%)
Varicose vein	6 (0.40%)	9 (0.61%)	0 (0.00%)	15 (0.46%)
Vasculitis	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
Venous hypertension	0 (0.00%)	1 (0.07%)	0 (0.00%)	1 (0.03%)
White coat hypertension	0 (0.00%)	2 (0.14%)	0 (0.00%)	2 (0.06%)

Other Relevant Findings

Not applicable

Conclusion:

Results from this long-term extension study confirm and further extend those of the Phase II and III feeder studies (ORION-3, ORION-9, ORION-10 and ORION-11). Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)/1.5 mL subcutaneous administered every 6 months continues to be safe and well-tolerated, and exhibits sustained, robust, and consistent reductions in low-density lipoprotein cholesterol (LDL-C). The majority of the subjects attained their global LDL-C lipid targets for their level of risk, during the study. Furthermore, sustained improvements in total cholesterol, triglycerides, and high density lipoprotein cholesterol (HDL-C) in study subjects were demonstrated.

Date of Clinical Trial Report

27 October 2023